https://trial.medpath.com/news/uw-medicine-launches-clinical-trial-of-cnp-103-to-preserve-insulin-production-in-type-1-diabetes 2026-04-24T01:03:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uw-medicine-launches-clinical-trial-of-cnp-103-to-preserve-insulin-production-in-type-1-diabetes 2026-04-24T01:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-strikes-final-drug-pricing-deal-with-white-house-offers-free-gene-therapy-for-rare-hearing-loss 2026-04-23T21:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-strikes-final-drug-pricing-deal-with-white-house-offers-free-gene-therapy-for-rare-hearing-loss 2026-04-23T21:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/tadv-procedure-shows-significant-quality-of-life-improvements-in-no-option-clti-patients 2026-04-23T17:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tadv-procedure-shows-significant-quality-of-life-improvements-in-no-option-clti-patients 2026-04-23T17:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/theialife-appoints-thomas-ruggia-as-ceo-to-lead-phase-3-development-of-first-in-class-oral-myopia-therapy 2026-04-23T17:05:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theialife-appoints-thomas-ruggia-as-ceo-to-lead-phase-3-development-of-first-in-class-oral-myopia-therapy 2026-04-23T17:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/asciminib-shows-sustained-efficacy-in-heavily-pretreated-cml-patients-with-39-achieving-major-molecular-response 2026-04-23T17:05:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asciminib-shows-sustained-efficacy-in-heavily-pretreated-cml-patients-with-39-achieving-major-molecular-response 2026-04-23T17:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/cumberland-pharmaceuticals-sells-commercial-portfolio-to-apotex-for-100m-refocuses-on-orphan-drug-pipeline 2026-04-23T17:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cumberland-pharmaceuticals-sells-commercial-portfolio-to-apotex-for-100m-refocuses-on-orphan-drug-pipeline 2026-04-23T17:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/microneedle-biosensor-enables-real-time-drug-clearance-monitoring-and-early-detection-of-kidney-and-liver-dysfunction 2026-04-23T17:04:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microneedle-biosensor-enables-real-time-drug-clearance-monitoring-and-early-detection-of-kidney-and-liver-dysfunction 2026-04-23T17:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-doses-first-patient-in-phase-2-3-trial-of-manganese-based-mri-contrast-agent 2026-04-23T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ge-healthcare-doses-first-patient-in-phase-2-3-trial-of-manganese-based-mri-contrast-agent 2026-04-23T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-reclassifies-cannabis-to-schedule-iii-opening-new-research-pathways 2026-04-23T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-reclassifies-cannabis-to-schedule-iii-opening-new-research-pathways 2026-04-23T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/recovery-trial-the-landmark-covid-19-study-that-saved-one-million-lives-worldwide 2026-04-23T17:04:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recovery-trial-the-landmark-covid-19-study-that-saved-one-million-lives-worldwide 2026-04-23T17:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/repertoire-immune-medicines-initiates-first-in-human-trial-of-novel-tcr-bispecific-therapy-for-advanced-solid-tumors 2026-04-23T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repertoire-immune-medicines-initiates-first-in-human-trial-of-novel-tcr-bispecific-therapy-for-advanced-solid-tumors 2026-04-23T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/paxlovid-speeds-recovery-but-fails-to-reduce-hospitalizations-in-vaccinated-covid-19-patients 2026-04-23T05:05:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paxlovid-speeds-recovery-but-fails-to-reduce-hospitalizations-in-vaccinated-covid-19-patients 2026-04-23T05:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/federal-judge-allows-eli-lilly-lawsuit-against-compounded-tirzepatide-seller-to-proceed 2026-04-23T05:05:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-judge-allows-eli-lilly-lawsuit-against-compounded-tirzepatide-seller-to-proceed 2026-04-23T05:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/vietnam-announces-plans-to-join-international-mrna-cancer-vaccine-clinical-trials-starting-2026 2026-04-23T05:05:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vietnam-announces-plans-to-join-international-mrna-cancer-vaccine-clinical-trials-starting-2026 2026-04-23T05:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/prestige-biopharma-files-patent-for-novel-subcutaneous-antibody-delivery-platform-idc224 2026-04-23T05:05:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prestige-biopharma-files-patent-for-novel-subcutaneous-antibody-delivery-platform-idc224 2026-04-23T05:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/certara-divests-regulatory-and-medical-writing-business-to-veristat-for-135-million-to-focus-on-ai-driven-drug-development 2026-04-23T01:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/certara-divests-regulatory-and-medical-writing-business-to-veristat-for-135-million-to-focus-on-ai-driven-drug-development 2026-04-23T01:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/xeltis-receives-eu-ce-mark-for-bioabsorbable-hemodialysis-graft-following-successful-120-patient-trial 2026-04-23T01:04:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xeltis-receives-eu-ce-mark-for-bioabsorbable-hemodialysis-graft-following-successful-120-patient-trial 2026-04-23T01:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/silo-pharma-targets-near-term-commercial-launch-of-ai-platform-as-ptsd-drug-spc-15-advances-toward-fda-engagement 2026-04-23T01:03:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silo-pharma-targets-near-term-commercial-launch-of-ai-platform-as-ptsd-drug-spc-15-advances-toward-fda-engagement 2026-04-23T01:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-advances-polymer-testing-for-pnkp-inhibitor-technology-ahead-of-ind-enabling-studies 2026-04-22T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onco-innovations-advances-polymer-testing-for-pnkp-inhibitor-technology-ahead-of-ind-enabling-studies 2026-04-22T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/six-year-old-girl-regains-vision-through-groundbreaking-nhs-gene-therapy-for-leber-s-congenital-amaurosis 2026-04-22T21:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/six-year-old-girl-regains-vision-through-groundbreaking-nhs-gene-therapy-for-leber-s-congenital-amaurosis 2026-04-22T21:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-gene-therapy-trial-for-type-1-diabetes-to-begin-this-year-with-kriya-839 2026-04-22T21:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-human-gene-therapy-trial-for-type-1-diabetes-to-begin-this-year-with-kriya-839 2026-04-22T21:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/10x-science-raises-4-8m-to-automate-protein-characterization-with-ai-platform 2026-04-22T21:05:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/10x-science-raises-4-8m-to-automate-protein-characterization-with-ai-platform 2026-04-22T21:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/evonik-invests-eur80-million-to-expand-biopharma-manufacturing-capacity-in-slovakia 2026-04-22T21:05:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evonik-invests-eur80-million-to-expand-biopharma-manufacturing-capacity-in-slovakia 2026-04-22T21:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-drug-dh20931-shows-promise-against-triple-negative-breast-cancer-through-novel-lipid-targeting-mechanism 2026-04-22T21:03:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-drug-dh20931-shows-promise-against-triple-negative-breast-cancer-through-novel-lipid-targeting-mechanism 2026-04-22T21:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-class-anti-netrin-1-antibody-shows-promise-in-pancreatic-cancer-phase-1b-trial 2026-04-22T17:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-class-anti-netrin-1-antibody-shows-promise-in-pancreatic-cancer-phase-1b-trial 2026-04-22T17:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/rafael-holdings-secures-exclusive-mit-license-for-cyclodextrin-therapy-targeting-apoe4-positive-alzheimer-s-patients 2026-04-22T17:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rafael-holdings-secures-exclusive-mit-license-for-cyclodextrin-therapy-targeting-apoe4-positive-alzheimer-s-patients 2026-04-22T17:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/demerx-receives-fda-clearance-for-novel-neuroplastogen-dmx-1001-to-treat-alcohol-use-disorder 2026-04-22T17:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/demerx-receives-fda-clearance-for-novel-neuroplastogen-dmx-1001-to-treat-alcohol-use-disorder 2026-04-22T17:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/made-scientific-partners-with-regenicin-to-advance-novaderm-autologous-skin-substitute-toward-fda-approval 2026-04-22T17:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/made-scientific-partners-with-regenicin-to-advance-novaderm-autologous-skin-substitute-toward-fda-approval 2026-04-22T17:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/mindera-health-receives-new-york-state-approval-for-mind-px-psoriasis-precision-medicine-test 2026-04-22T17:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindera-health-receives-new-york-state-approval-for-mind-px-psoriasis-precision-medicine-test 2026-04-22T17:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-pegrizeprument-for-heart-transplant-rejection-prevention 2026-04-22T17:05:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-pegrizeprument-for-heart-transplant-rejection-prevention 2026-04-22T17:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-pharmaceuticals-acquires-kashiv-biosciences-for-750-million-to-create-global-biosimilar-leader 2026-04-22T17:04:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-pharmaceuticals-acquires-kashiv-biosciences-for-750-million-to-create-global-biosimilar-leader 2026-04-22T17:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/united-laboratories-advances-dual-pipeline-with-fda-approval-for-tul321-and-china-approval-for-dupilumab-biosimilar 2026-04-22T17:04:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-laboratories-advances-dual-pipeline-with-fda-approval-for-tul321-and-china-approval-for-dupilumab-biosimilar 2026-04-22T17:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-s-opaganib-shows-promise-in-neuroblastoma-and-triple-negative-breast-cancer-preclinical-studies 2026-04-22T17:04:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-s-opaganib-shows-promise-in-neuroblastoma-and-triple-negative-breast-cancer-preclinical-studies 2026-04-22T17:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/carob-concentrate-shows-promise-for-prediabetes-management-in-clinical-trial 2026-04-22T17:04:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carob-concentrate-shows-promise-for-prediabetes-management-in-clinical-trial 2026-04-22T17:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/thryv-therapeutics-initiates-phase-2-3-trial-for-long-qt-syndrome-treatment-receives-fda-fast-track-designation 2026-04-22T17:04:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thryv-therapeutics-initiates-phase-2-3-trial-for-long-qt-syndrome-treatment-receives-fda-fast-track-designation 2026-04-22T17:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/aavantgarde-presents-interim-luce-1-trial-data-for-usher-syndrome-1b-gene-therapy-at-arvo-2026 2026-04-22T13:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aavantgarde-presents-interim-luce-1-trial-data-for-usher-syndrome-1b-gene-therapy-at-arvo-2026 2026-04-22T13:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharma-companies-compete-for-8-billion-inhibrx-cancer-drug-that-could-enhance-keytruda 2026-04-22T13:07:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharma-companies-compete-for-8-billion-inhibrx-cancer-drug-that-could-enhance-keytruda 2026-04-22T13:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/puretech-s-lyt-200-shows-promising-results-in-phase-1b-trial-for-relapsed-refractory-blood-cancers 2026-04-22T13:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/puretech-s-lyt-200-shows-promising-results-in-phase-1b-trial-for-relapsed-refractory-blood-cancers 2026-04-22T13:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/hvivo-secures-landmark-phase-iii-whooping-cough-vaccine-trial-and-ps6m-influenza-drug-contract 2026-04-22T13:05:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hvivo-secures-landmark-phase-iii-whooping-cough-vaccine-trial-and-ps6m-influenza-drug-contract 2026-04-22T13:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/ractigen-s-rag-17-shows-81-reduction-in-neurodegeneration-biomarker-in-sod1-als-phase-i-trial 2026-04-22T09:10:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ractigen-s-rag-17-shows-81-reduction-in-neurodegeneration-biomarker-in-sod1-als-phase-i-trial 2026-04-22T09:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/calluna-pharma-completes-enrollment-in-phase-2-aurora-study-of-cal101-for-idiopathic-pulmonary-fibrosis 2026-04-22T09:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calluna-pharma-completes-enrollment-in-phase-2-aurora-study-of-cal101-for-idiopathic-pulmonary-fibrosis 2026-04-22T09:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/dayspring-pharma-s-cg2001-foam-shows-50-efficacy-improvement-in-phase-ii-androgenetic-alopecia-trial 2026-04-22T09:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dayspring-pharma-s-cg2001-foam-shows-50-efficacy-improvement-in-phase-ii-androgenetic-alopecia-trial 2026-04-22T09:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/neuro-symbolic-ai-shows-distinct-advantages-over-conventional-llms-for-mental-health-guidance 2026-04-22T07:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuro-symbolic-ai-shows-distinct-advantages-over-conventional-llms-for-mental-health-guidance 2026-04-22T07:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-advances-first-in-class-ibi363-to-pivotal-trials-for-immunotherapy-resistant-lung-cancer 2026-04-22T05:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-advances-first-in-class-ibi363-to-pivotal-trials-for-immunotherapy-resistant-lung-cancer 2026-04-22T05:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/novi-health-s-hybrid-care-model-achieves-clinical-trial-level-weight-loss-in-real-world-glp-1-treatment 2026-04-22T05:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novi-health-s-hybrid-care-model-achieves-clinical-trial-level-weight-loss-in-real-world-glp-1-treatment 2026-04-22T05:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/rgenta-therapeutics-to-present-phase-1-clinical-data-on-rna-targeting-cancer-drug-rgt-61159-at-asco-2026 2026-04-22T01:04:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rgenta-therapeutics-to-present-phase-1-clinical-data-on-rna-targeting-cancer-drug-rgt-61159-at-asco-2026 2026-04-22T01:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/sidra-medicine-becomes-first-hospital-in-qatar-to-offer-crispr-gene-therapy-for-sickle-cell-disease-and-thalassemia 2026-04-22T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sidra-medicine-becomes-first-hospital-in-qatar-to-offer-crispr-gene-therapy-for-sickle-cell-disease-and-thalassemia 2026-04-22T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/kyverna-s-car-t-therapy-for-stiff-person-syndrome-advances-to-bla-filing-based-on-natural-history-study 2026-04-22T01:04:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kyverna-s-car-t-therapy-for-stiff-person-syndrome-advances-to-bla-filing-based-on-natural-history-study 2026-04-22T01:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/digital-twins-emerge-as-breakthrough-in-rare-disease-research-certara-s-piet-van-der-graaf-explains 2026-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digital-twins-emerge-as-breakthrough-in-rare-disease-research-certara-s-piet-van-der-graaf-explains 2026-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-led-studies-demonstrate-breakthrough-treatments-for-challenging-women-s-cancers 2026-04-21T21:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-led-studies-demonstrate-breakthrough-treatments-for-challenging-women-s-cancers 2026-04-21T21:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/injectable-nivolumab-shows-promise-for-precancerous-oral-lesions-in-phase-i-trial 2026-04-21T21:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/injectable-nivolumab-shows-promise-for-precancerous-oral-lesions-in-phase-i-trial 2026-04-21T21:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/early-myocarditis-onset-after-immunotherapy-may-predict-treatment-related-fatality 2026-04-21T21:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-myocarditis-onset-after-immunotherapy-may-predict-treatment-related-fatality 2026-04-21T21:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/enspryng-achieves-68-reduction-in-mogad-relapses-in-pivotal-phase-iii-trial 2026-04-21T21:06:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enspryng-achieves-68-reduction-in-mogad-relapses-in-pivotal-phase-iii-trial 2026-04-21T21:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-to-present-positive-phase-3-frontmind-data-for-tafasitamab-in-first-line-dlbcl-at-asco-2026 2026-04-21T21:05:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-to-present-positive-phase-3-frontmind-data-for-tafasitamab-in-first-line-dlbcl-at-asco-2026 2026-04-21T21:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-expanded-indications-for-sinefix-orthopedic-implant-across-multiple-soft-tissue-repair-applications 2026-04-21T21:05:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-expanded-indications-for-sinefix-orthopedic-implant-across-multiple-soft-tissue-repair-applications 2026-04-21T21:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/cerracap-ventures-invests-in-nephronomics-to-advance-ai-driven-kidney-disease-drug-discovery 2026-04-21T21:05:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cerracap-ventures-invests-in-nephronomics-to-advance-ai-driven-kidney-disease-drug-discovery 2026-04-21T21:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-blood-collection-for-avertd-genetic-test-to-assess-opioid-use-disorder-risk 2026-04-21T21:04:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-blood-collection-for-avertd-genetic-test-to-assess-opioid-use-disorder-risk 2026-04-21T21:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/aulos-bioscience-reports-promising-phase-1-2-results-for-ai-designed-melanoma-therapy-at-asco-2026 2026-04-21T17:17:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aulos-bioscience-reports-promising-phase-1-2-results-for-ai-designed-melanoma-therapy-at-asco-2026 2026-04-21T17:17:12+00:00 hourly 0.9 https://trial.medpath.com/news/crown-bioscience-and-turbine-partner-to-integrate-ai-driven-drug-discovery-with-organoid-validation-platform 2026-04-21T17:15:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crown-bioscience-and-turbine-partner-to-integrate-ai-driven-drug-discovery-with-organoid-validation-platform 2026-04-21T17:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/cemdisiran-achieves-breakthrough-results-in-phase-3-myasthenia-gravis-trial-positioning-for-first-sirna-approval 2026-04-21T17:15:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cemdisiran-achieves-breakthrough-results-in-phase-3-myasthenia-gravis-trial-positioning-for-first-sirna-approval 2026-04-21T17:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/gen1e-and-rubicon-research-form-strategic-partnership-to-advance-ai-driven-precision-medicine-platform 2026-04-21T17:15:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gen1e-and-rubicon-research-form-strategic-partnership-to-advance-ai-driven-precision-medicine-platform 2026-04-21T17:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/minaris-achieves-100-manufacturing-success-rate-for-chimeric-therapeutics-cdh17-car-t-cancer-program 2026-04-21T17:14:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minaris-achieves-100-manufacturing-success-rate-for-chimeric-therapeutics-cdh17-car-t-cancer-program 2026-04-21T17:14:19+00:00 hourly 0.9 https://trial.medpath.com/news/bpgbio-appoints-former-oxford-innovation-chief-chas-bountra-as-cso-to-advance-mitochondrial-therapeutics-pipeline 2026-04-21T17:13:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bpgbio-appoints-former-oxford-innovation-chief-chas-bountra-as-cso-to-advance-mitochondrial-therapeutics-pipeline 2026-04-21T17:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/bioaegis-partners-with-prenosis-to-develop-ai-driven-precision-medicine-for-ards-treatment 2026-04-21T17:12:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioaegis-partners-with-prenosis-to-develop-ai-driven-precision-medicine-for-ards-treatment 2026-04-21T17:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/puma-biotechnology-raises-2026-revenue-outlook-on-strong-nerlynx-demand-advances-alisertib-pipeline 2026-04-21T17:12:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/puma-biotechnology-raises-2026-revenue-outlook-on-strong-nerlynx-demand-advances-alisertib-pipeline 2026-04-21T17:12:02+00:00 hourly 0.9 https://trial.medpath.com/news/star-therapeutics-receives-fda-rare-pediatric-disease-and-breakthrough-therapy-designations-for-vga039-in-von-willebrand-disease 2026-04-21T17:11:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/star-therapeutics-receives-fda-rare-pediatric-disease-and-breakthrough-therapy-designations-for-vga039-in-von-willebrand-disease 2026-04-21T17:11:18+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-health-launches-spire-platform-to-transform-post-approval-clinical-evidence-generation 2026-04-21T17:10:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paradigm-health-launches-spire-platform-to-transform-post-approval-clinical-evidence-generation 2026-04-21T17:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/tortugas-neuroscience-emerges-from-stealth-with-106m-to-advance-cns-drug-pipeline-licensed-from-eisai-and-hansoh 2026-04-21T17:10:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tortugas-neuroscience-emerges-from-stealth-with-106m-to-advance-cns-drug-pipeline-licensed-from-eisai-and-hansoh 2026-04-21T17:10:45+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-advances-ai-driven-heart-failure-monitoring-with-70-prediction-accuracy 2026-04-21T17:03:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-advances-ai-driven-heart-failure-monitoring-with-70-prediction-accuracy 2026-04-21T17:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/inbrain-completes-first-in-human-trial-of-graphene-brain-interface-with-no-safety-issues 2026-04-21T13:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inbrain-completes-first-in-human-trial-of-graphene-brain-interface-with-no-safety-issues 2026-04-21T13:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-draft-guidance-on-fermentation-derived-antibiotics-sparks-industry-calls-for-global-harmonization 2026-04-21T13:04:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-draft-guidance-on-fermentation-derived-antibiotics-sparks-industry-calls-for-global-harmonization 2026-04-21T13:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/flagship-pioneering-launches-serif-biomedicines-with-50m-to-pioneer-modified-dna-therapeutics 2026-04-21T13:03:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flagship-pioneering-launches-serif-biomedicines-with-50m-to-pioneer-modified-dna-therapeutics 2026-04-21T13:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/addex-gabab-pam-candidate-shows-promising-anti-cough-activity-in-non-human-primate-studies 2026-04-21T09:05:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/addex-gabab-pam-candidate-shows-promising-anti-cough-activity-in-non-human-primate-studies 2026-04-21T09:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/leinco-technologies-and-cellcarta-form-strategic-partnership-to-advance-proteomics-in-immuno-oncology-drug-development 2026-04-21T09:04:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leinco-technologies-and-cellcarta-form-strategic-partnership-to-advance-proteomics-in-immuno-oncology-drug-development 2026-04-21T09:04:34+00:00 hourly 0.9 https://trial.medpath.com/news/lirum-therapeutics-lx-101-shows-promising-preclinical-activity-in-ewing-sarcoma-advances-to-rapid-platform-trial 2026-04-21T05:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lirum-therapeutics-lx-101-shows-promising-preclinical-activity-in-ewing-sarcoma-advances-to-rapid-platform-trial 2026-04-21T05:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/controlling-ai-hallucinations-building-evidence-based-trust-in-clinical-and-scientific-workflows 2026-04-21T04:44:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/controlling-ai-hallucinations-building-evidence-based-trust-in-clinical-and-scientific-workflows 2026-04-21T04:44:25+00:00 hourly 0.9 https://trial.medpath.com/news/conavi-medical-receives-fda-clearance-for-first-hybrid-ivus-oct-intravascular-imaging-system 2026-04-21T01:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/conavi-medical-receives-fda-clearance-for-first-hybrid-ivus-oct-intravascular-imaging-system 2026-04-21T01:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-nmpa-strengthens-contract-manufacturing-oversight-sets-new-quality-obligations-for-mahs-and-cmos 2026-04-21T01:04:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-nmpa-strengthens-contract-manufacturing-oversight-sets-new-quality-obligations-for-mahs-and-cmos 2026-04-21T01:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/rusan-pharma-secures-pmda-japan-gmp-approval-for-api-and-injectable-manufacturing-facilities 2026-04-21T01:04:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rusan-pharma-secures-pmda-japan-gmp-approval-for-api-and-injectable-manufacturing-facilities 2026-04-21T01:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/inhibrx-to-present-clinical-update-on-ozekibart-in-late-line-colorectal-cancer 2026-04-21T01:04:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhibrx-to-present-clinical-update-on-ozekibart-in-late-line-colorectal-cancer 2026-04-21T01:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/lincotek-receives-fda-clearance-for-sportlinc-ankle-stabilization-device-targets-orthopedic-oem-market 2026-04-21T01:04:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lincotek-receives-fda-clearance-for-sportlinc-ankle-stabilization-device-targets-orthopedic-oem-market 2026-04-21T01:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/iu-led-coalition-secures-nsf-impact-engine-designation-to-accelerate-musculoskeletal-innovation 2026-04-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iu-led-coalition-secures-nsf-impact-engine-designation-to-accelerate-musculoskeletal-innovation 2026-04-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/crexont-shows-superior-efficacy-in-phase-4-trial-delivering-over-3-additional-hours-of-daily-good-on-time-for-parkinson-s-patients 2026-04-20T22:44:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crexont-shows-superior-efficacy-in-phase-4-trial-delivering-over-3-additional-hours-of-daily-good-on-time-for-parkinson-s-patients 2026-04-20T22:44:31+00:00 hourly 0.9 https://trial.medpath.com/news/flatiron-health-publishes-first-peer-reviewed-validation-framework-for-ai-extracted-real-world-oncology-data 2026-04-20T22:44:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flatiron-health-publishes-first-peer-reviewed-validation-framework-for-ai-extracted-real-world-oncology-data 2026-04-20T22:44:12+00:00 hourly 0.9 https://trial.medpath.com/news/phase-i-lung-cancer-trials-consolidate-at-major-u-s-medical-centers-raising-access-concerns 2026-04-20T22:39:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-i-lung-cancer-trials-consolidate-at-major-u-s-medical-centers-raising-access-concerns 2026-04-20T22:39:55+00:00 hourly 0.9 https://trial.medpath.com/news/accord-biopharma-s-ustekinumab-biosimilar-imuldosa-gains-preferred-status-on-cigna-healthcare-formularies 2026-04-20T18:43:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accord-biopharma-s-ustekinumab-biosimilar-imuldosa-gains-preferred-status-on-cigna-healthcare-formularies 2026-04-20T18:43:54+00:00 hourly 0.9 https://trial.medpath.com/news/huxley-health-launches-aerasyn-biotech-division-secures-15m-financing-for-psychedelic-therapeutics-platform 2026-04-20T18:41:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huxley-health-launches-aerasyn-biotech-division-secures-15m-financing-for-psychedelic-therapeutics-platform 2026-04-20T18:41:10+00:00 hourly 0.9 https://trial.medpath.com/news/abogen-s-mrna-encoded-t-cell-engager-abo2203-shows-promise-in-b-cell-lymphoma-with-superior-safety-profile 2026-04-20T18:37:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abogen-s-mrna-encoded-t-cell-engager-abo2203-shows-promise-in-b-cell-lymphoma-with-superior-safety-profile 2026-04-20T18:37:22+00:00 hourly 0.9 https://trial.medpath.com/news/viewsml-raises-4-9m-to-commercialize-ai-powered-virtual-biomarker-staining-technology 2026-04-20T18:36:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viewsml-raises-4-9m-to-commercialize-ai-powered-virtual-biomarker-staining-technology 2026-04-20T18:36:31+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-jamp-pharma-s-golimumab-biosimilar-prupgolyv-for-autoimmune-diseases 2026-04-20T18:35:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-jamp-pharma-s-golimumab-biosimilar-prupgolyv-for-autoimmune-diseases 2026-04-20T18:35:41+00:00 hourly 0.9 https://trial.medpath.com/news/orion-pharma-s-odm-212-receives-fda-orphan-drug-designation-for-mesothelioma-treatment 2026-04-20T18:35:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orion-pharma-s-odm-212-receives-fda-orphan-drug-designation-for-mesothelioma-treatment 2026-04-20T18:35:33+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-launches-ps150m-ai-accelerator-in-london-to-advance-drug-discovery 2026-04-20T18:35:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-launches-ps150m-ai-accelerator-in-london-to-advance-drug-discovery 2026-04-20T18:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/sapience-therapeutics-reports-47-response-rate-for-first-in-class-b-catenin-antagonist-st316-in-second-line-colorectal-cancer 2026-04-20T18:35:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sapience-therapeutics-reports-47-response-rate-for-first-in-class-b-catenin-antagonist-st316-in-second-line-colorectal-cancer 2026-04-20T18:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/st-david-s-south-austin-medical-center-enrolls-first-patient-globally-in-phase-iii-car-t-cell-trial-for-aggressive-large-b-cell-lymphoma 2026-04-20T18:33:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/st-david-s-south-austin-medical-center-enrolls-first-patient-globally-in-phase-iii-car-t-cell-trial-for-aggressive-large-b-cell-lymphoma 2026-04-20T18:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/jeeva-clinical-trials-acquires-clintelligence-ai-to-transform-clinical-trial-design-and-reduce-development-failures 2026-04-20T18:33:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jeeva-clinical-trials-acquires-clintelligence-ai-to-transform-clinical-trial-design-and-reduce-development-failures 2026-04-20T18:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-acquires-global-rights-to-felzartamab-with-850-million-deal-for-greater-china-assets 2026-04-20T13:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-acquires-global-rights-to-felzartamab-with-850-million-deal-for-greater-china-assets 2026-04-20T13:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/toronto-ai-startup-biossil-raises-70m-to-resurrect-failed-drug-candidates-using-large-language-models 2026-04-20T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/toronto-ai-startup-biossil-raises-70m-to-resurrect-failed-drug-candidates-using-large-language-models 2026-04-20T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/chong-kun-dang-enrolls-first-u-s-patient-in-global-phase-1-2a-trial-of-adc-cancer-drug-ckd-703 2026-04-20T13:05:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chong-kun-dang-enrolls-first-u-s-patient-in-global-phase-1-2a-trial-of-adc-cancer-drug-ckd-703 2026-04-20T13:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-etavopivat-achieves-breakthrough-results-in-phase-3-sickle-cell-disease-trial 2026-04-20T13:04:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-etavopivat-achieves-breakthrough-results-in-phase-3-sickle-cell-disease-trial 2026-04-20T13:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/deep-learning-and-brain-organoids-uncover-azole-antifungals-as-repurposable-drug-candidates-for-leigh-syndrome 2026-04-20T13:04:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deep-learning-and-brain-organoids-uncover-azole-antifungals-as-repurposable-drug-candidates-for-leigh-syndrome 2026-04-20T13:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/askbio-advances-commercial-scale-manufacturing-for-parkinson-s-gene-therapy-in-phase-ii-trial 2026-04-20T13:04:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/askbio-advances-commercial-scale-manufacturing-for-parkinson-s-gene-therapy-in-phase-ii-trial 2026-04-20T13:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/bracco-imaging-and-nyu-langone-health-form-strategic-alliance-to-advance-medical-imaging-innovation 2026-04-20T13:03:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bracco-imaging-and-nyu-langone-health-form-strategic-alliance-to-advance-medical-imaging-innovation 2026-04-20T13:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/cellbxhealth-partners-with-royal-marsden-to-enhance-lung-cancer-treatment-through-ctc-dna-analysis 2026-04-20T13:03:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellbxhealth-partners-with-royal-marsden-to-enhance-lung-cancer-treatment-through-ctc-dna-analysis 2026-04-20T13:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/cumberland-pharmaceuticals-receives-fda-approval-for-expanded-caldolor-indication-in-postoperative-pain-management 2026-04-20T09:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cumberland-pharmaceuticals-receives-fda-approval-for-expanded-caldolor-indication-in-postoperative-pain-management 2026-04-20T09:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/penn-launches-18-million-ai-driven-rna-foundry-to-democratize-mrna-technology-beyond-vaccines 2026-04-20T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penn-launches-18-million-ai-driven-rna-foundry-to-democratize-mrna-technology-beyond-vaccines 2026-04-20T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-t-cell-receptor-therapy-for-solid-tumors-in-synovial-sarcoma-patients 2026-04-20T09:03:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-t-cell-receptor-therapy-for-solid-tumors-in-synovial-sarcoma-patients 2026-04-20T09:03:34+00:00 hourly 0.9 https://trial.medpath.com/news/hk-inno-n-partners-with-nextgen-to-advance-ipf-drug-nxc680-into-phase-1-clinical-trials 2026-04-20T05:03:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hk-inno-n-partners-with-nextgen-to-advance-ipf-drug-nxc680-into-phase-1-clinical-trials 2026-04-20T05:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/nexalis-therapeutics-initiates-phase-2-trial-for-irx-211-in-breakthrough-cancer-pain 2026-04-20T05:03:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nexalis-therapeutics-initiates-phase-2-trial-for-irx-211-in-breakthrough-cancer-pain 2026-04-20T05:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/hiv-treatment-reverses-accelerated-biological-aging-by-nearly-four-years-swiss-study-reveals 2026-04-20T01:04:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hiv-treatment-reverses-accelerated-biological-aging-by-nearly-four-years-swiss-study-reveals 2026-04-20T01:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-kras-drug-shows-strong-results-at-aacr-2026 2026-04-20T01:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolution-medicines-kras-drug-shows-strong-results-at-aacr-2026 2026-04-20T01:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/xuanzhu-biopharma-s-diluoake-demonstrates-superior-efficacy-over-crizotinib-in-phase-iii-alk-positive-nsclc-trial 2026-04-19T17:03:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xuanzhu-biopharma-s-diluoake-demonstrates-superior-efficacy-over-crizotinib-in-phase-iii-alk-positive-nsclc-trial 2026-04-19T17:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-confirms-consistent-efficacy-of-osteoporosis-biosimilar-obodence-across-diverse-patient-populations 2026-04-19T09:04:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-bioepis-confirms-consistent-efficacy-of-osteoporosis-biosimilar-obodence-across-diverse-patient-populations 2026-04-19T09:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-win-3-million-prize-for-breakthrough-research-leading-to-first-crispr-sickle-cell-therapy 2026-04-19T05:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-win-3-million-prize-for-breakthrough-research-leading-to-first-crispr-sickle-cell-therapy 2026-04-19T05:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-first-warning-letter-for-inappropriate-ai-use-in-drug-manufacturing 2026-04-19T01:04:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-first-warning-letter-for-inappropriate-ai-use-in-drug-manufacturing 2026-04-19T01:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/biolamina-secures-eur20m-eib-loan-to-scale-laminin-technology-for-cell-therapy-manufacturing 2026-04-19T01:04:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biolamina-secures-eur20m-eib-loan-to-scale-laminin-technology-for-cell-therapy-manufacturing 2026-04-19T01:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/philadelphia-scientists-win-3-million-breakthrough-prize-for-first-fda-approved-gene-therapy-for-inherited-blindness 2026-04-19T01:04:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/philadelphia-scientists-win-3-million-breakthrough-prize-for-first-fda-approved-gene-therapy-for-inherited-blindness 2026-04-19T01:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-se-s-drug-discovery-partnership-model-gains-traction-as-pharma-outsourcing-accelerates 2026-04-18T21:05:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evotec-se-s-drug-discovery-partnership-model-gains-traction-as-pharma-outsourcing-accelerates 2026-04-18T21:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/extended-immunotherapy-shows-safety-profile-in-rare-alveolar-soft-part-sarcoma-beyond-standard-two-year-treatment 2026-04-18T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extended-immunotherapy-shows-safety-profile-in-rare-alveolar-soft-part-sarcoma-beyond-standard-two-year-treatment 2026-04-18T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/blood-pressure-drug-candesartan-cilexetil-shows-promise-against-mrsa-infections-in-laboratory-study 2026-04-18T17:10:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-pressure-drug-candesartan-cilexetil-shows-promise-against-mrsa-infections-in-laboratory-study 2026-04-18T17:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-nuvaxovid-covid-19-vaccine-demonstrates-superior-tolerability-profile-compared-to-mrna-vaccine-in-head-to-head-study 2026-04-18T13:03:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-nuvaxovid-covid-19-vaccine-demonstrates-superior-tolerability-profile-compared-to-mrna-vaccine-in-head-to-head-study 2026-04-18T13:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/global-partners-back-africa-s-first-end-to-end-multi-vaccine-manufacturing-hub-in-south-africa 2026-04-18T09:05:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-partners-back-africa-s-first-end-to-end-multi-vaccine-manufacturing-hub-in-south-africa 2026-04-18T09:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/model-medicines-secures-first-us-patent-for-ai-discovered-broad-spectrum-antiviral-mdl-001 2026-04-18T09:03:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/model-medicines-secures-first-us-patent-for-ai-discovered-broad-spectrum-antiviral-mdl-001 2026-04-18T09:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/rznomics-rna-therapy-shows-23-complete-response-rate-in-liver-cancer-trial 2026-04-18T09:03:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rznomics-rna-therapy-shows-23-complete-response-rate-in-liver-cancer-trial 2026-04-18T09:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/signant-health-acquires-ametris-to-create-integrated-ecoa-and-digital-biomarker-platform 2026-04-18T09:03:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/signant-health-acquires-ametris-to-create-integrated-ecoa-and-digital-biomarker-platform 2026-04-18T09:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/prame-directed-tcr-cell-therapy-achieves-deep-remission-in-pediatric-nephroblastoma-patient 2026-04-18T05:05:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prame-directed-tcr-cell-therapy-achieves-deep-remission-in-pediatric-nephroblastoma-patient 2026-04-18T05:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/odyssey-therapeutics-files-for-232-million-nasdaq-ipo-to-advance-autoimmune-disease-pipeline 2026-04-18T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/odyssey-therapeutics-files-for-232-million-nasdaq-ipo-to-advance-autoimmune-disease-pipeline 2026-04-18T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/asco-expands-tapur-study-with-first-antibody-drug-conjugate-and-braf-mek-inhibitor-combination 2026-04-18T01:03:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asco-expands-tapur-study-with-first-antibody-drug-conjugate-and-braf-mek-inhibitor-combination 2026-04-18T01:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/biolojic-design-s-ai-designed-bd200-shows-superior-anti-tumor-activity-in-preclinical-studies-targeting-dual-cancer-antigens 2026-04-17T21:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biolojic-design-s-ai-designed-bd200-shows-superior-anti-tumor-activity-in-preclinical-studies-targeting-dual-cancer-antigens 2026-04-17T21:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/onconano-s-ph-sensitive-nanotechnology-platform-shows-promise-for-antigen-independent-cancer-drug-delivery 2026-04-17T21:04:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onconano-s-ph-sensitive-nanotechnology-platform-shows-promise-for-antigen-independent-cancer-drug-delivery 2026-04-17T21:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/waters-receives-fda-510-k-clearance-for-bd-bactec-fxi-culture-system-accelerating-bloodstream-infection-diagnostics 2026-04-17T21:04:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/waters-receives-fda-510-k-clearance-for-bd-bactec-fxi-culture-system-accelerating-bloodstream-infection-diagnostics 2026-04-17T21:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/shanghai-bao-pharmaceuticals-wins-nmpa-approval-to-begin-clinical-trials-of-world-s-first-recombinant-ulinastatin-bj044 2026-04-17T21:04:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shanghai-bao-pharmaceuticals-wins-nmpa-approval-to-begin-clinical-trials-of-world-s-first-recombinant-ulinastatin-bj044 2026-04-17T21:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/vosoritide-shows-promise-for-rare-genetic-growth-disorders-beyond-achondroplasia-in-phase-2-trial 2026-04-17T21:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vosoritide-shows-promise-for-rare-genetic-growth-disorders-beyond-achondroplasia-in-phase-2-trial 2026-04-17T21:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/salubris-biotherapeutics-reports-promising-phase-1-2-data-for-5t4-targeted-adc-jk06-in-multiple-solid-tumors 2026-04-17T21:03:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salubris-biotherapeutics-reports-promising-phase-1-2-data-for-5t4-targeted-adc-jk06-in-multiple-solid-tumors 2026-04-17T21:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-acquires-neurona-therapeutics-for-1-15-billion-to-advance-regenerative-cell-therapy-for-drug-resistant-epilepsy 2026-04-17T21:03:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-acquires-neurona-therapeutics-for-1-15-billion-to-advance-regenerative-cell-therapy-for-drug-resistant-epilepsy 2026-04-17T21:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-clinical-trial-shows-aerobic-exercise-lowers-long-term-cortisol-rewiring-stress-biology 2026-04-17T19:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-clinical-trial-shows-aerobic-exercise-lowers-long-term-cortisol-rewiring-stress-biology 2026-04-17T19:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/byondis-unveils-novel-adc-platforms-to-combat-cancer-drug-resistance-at-aacr-2026 2026-04-17T17:11:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/byondis-unveils-novel-adc-platforms-to-combat-cancer-drug-resistance-at-aacr-2026 2026-04-17T17:11:50+00:00 hourly 0.9 https://trial.medpath.com/news/prmt5-inhibition-sensitizes-b-cell-lymphoma-to-ferroptosis-via-atf5-slc7a11-axis 2026-04-17T17:11:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prmt5-inhibition-sensitizes-b-cell-lymphoma-to-ferroptosis-via-atf5-slc7a11-axis 2026-04-17T17:11:49+00:00 hourly 0.9 https://trial.medpath.com/news/luxturna-gene-therapy-shows-functional-benefits-despite-structural-decline-in-real-world-study 2026-04-17T17:10:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luxturna-gene-therapy-shows-functional-benefits-despite-structural-decline-in-real-world-study 2026-04-17T17:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-seeks-orphan-drug-designation-for-skinject-in-rare-gorlin-syndrome 2026-04-17T17:09:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicus-pharma-seeks-orphan-drug-designation-for-skinject-in-rare-gorlin-syndrome 2026-04-17T17:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/marengo-therapeutics-reports-confirmed-complete-responses-in-phase-2-trial-of-invikafusp-alfa-plus-trodelvy-for-metastatic-breast-cancer 2026-04-17T17:09:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marengo-therapeutics-reports-confirmed-complete-responses-in-phase-2-trial-of-invikafusp-alfa-plus-trodelvy-for-metastatic-breast-cancer 2026-04-17T17:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/penetrium-bioscience-claims-breakthrough-in-tumor-microenvironment-targeting-to-overcome-cancer-drug-resistance 2026-04-17T17:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penetrium-bioscience-claims-breakthrough-in-tumor-microenvironment-targeting-to-overcome-cancer-drug-resistance 2026-04-17T17:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/biomarker-led-trials-emerge-as-key-strategy-for-precision-psychiatry-development 2026-04-17T13:05:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarker-led-trials-emerge-as-key-strategy-for-precision-psychiatry-development 2026-04-17T13:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/donor-derived-cell-therapy-enables-immunosuppression-withdrawal-in-liver-transplant-patients 2026-04-17T13:04:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/donor-derived-cell-therapy-enables-immunosuppression-withdrawal-in-liver-transplant-patients 2026-04-17T13:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/bioxodes-strengthens-clinical-advisory-board-and-advances-biox-101-pivotal-trial-for-intracerebral-hemorrhage 2026-04-17T13:03:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxodes-strengthens-clinical-advisory-board-and-advances-biox-101-pivotal-trial-for-intracerebral-hemorrhage 2026-04-17T13:03:34+00:00 hourly 0.9 https://trial.medpath.com/news/merck-launches-first-pivotal-trial-of-cd19-t-cell-engager-mk-1045-against-blincyto-in-b-all 2026-04-17T13:03:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-launches-first-pivotal-trial-of-cd19-t-cell-engager-mk-1045-against-blincyto-in-b-all 2026-04-17T13:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/naronapride-shows-statistically-significant-improvement-in-gastroparesis-symptoms-in-phase-2b-move-it-trial 2026-04-17T09:04:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/naronapride-shows-statistically-significant-improvement-in-gastroparesis-symptoms-in-phase-2b-move-it-trial 2026-04-17T09:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-s-enstilar-foam-receives-nmpa-approval-for-plaque-psoriasis-treatment-in-china 2026-04-17T09:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leo-pharma-s-enstilar-foam-receives-nmpa-approval-for-plaque-psoriasis-treatment-in-china 2026-04-17T09:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/iran-war-exposes-medicine-pricing-s-deep-oil-vulnerability-methotrexate-costs-surge-up-to-87 2026-04-17T07:44:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iran-war-exposes-medicine-pricing-s-deep-oil-vulnerability-methotrexate-costs-surge-up-to-87 2026-04-17T07:44:41+00:00 hourly 0.9 https://trial.medpath.com/news/biomed-x-and-servier-launch-ai-driven-bispecific-antibody-engineering-team-in-france 2026-04-17T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomed-x-and-servier-launch-ai-driven-bispecific-antibody-engineering-team-in-france 2026-04-17T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/khondrion-initiates-pivotal-phase-3-trial-for-sonlicromanol-in-rare-mitochondrial-disease 2026-04-17T01:04:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/khondrion-initiates-pivotal-phase-3-trial-for-sonlicromanol-in-rare-mitochondrial-disease 2026-04-17T01:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/bio-protocol-launches-openlabs-platform-at-desci-berlin-merging-ai-with-decentralized-biotech-funding 2026-04-16T21:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-protocol-launches-openlabs-platform-at-desci-berlin-merging-ai-with-decentralized-biotech-funding 2026-04-16T21:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-s-inb03-shows-promise-in-overcoming-her2-positive-breast-cancer-drug-resistance 2026-04-16T21:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-s-inb03-shows-promise-in-overcoming-her2-positive-breast-cancer-drug-resistance 2026-04-16T21:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-receives-fda-approval-for-generic-methotrexate-injection 2026-04-16T21:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alembic-pharmaceuticals-receives-fda-approval-for-generic-methotrexate-injection 2026-04-16T21:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-encourages-testosterone-therapy-manufacturers-to-pursue-expanded-indication-for-low-libido 2026-04-16T21:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-encourages-testosterone-therapy-manufacturers-to-pursue-expanded-indication-for-low-libido 2026-04-16T21:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-generic-version-of-farxiga-for-type-2-diabetes-and-cardiovascular-disease 2026-04-16T21:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-generic-version-of-farxiga-for-type-2-diabetes-and-cardiovascular-disease 2026-04-16T21:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-launches-multi-cancer-study-of-quest-diagnostics-haystack-mrd-test-across-14-sites 2026-04-16T21:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/city-of-hope-launches-multi-cancer-study-of-quest-diagnostics-haystack-mrd-test-across-14-sites 2026-04-16T21:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/meiragtx-reacquires-gene-therapy-botaretigene-sparoparvovec-from-johnson-johnson-for-x-linked-retinitis-pigmentosa-treatment 2026-04-16T21:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meiragtx-reacquires-gene-therapy-botaretigene-sparoparvovec-from-johnson-johnson-for-x-linked-retinitis-pigmentosa-treatment 2026-04-16T21:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-pharma-receives-clinical-trial-approvals-for-five-oncology-drugs-including-novel-kras-g12d-inhibitor 2026-04-16T21:04:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hengrui-pharma-receives-clinical-trial-approvals-for-five-oncology-drugs-including-novel-kras-g12d-inhibitor 2026-04-16T21:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-researchers-uncover-nat10-myc-pathway-driving-immunotherapy-resistance-in-colorectal-cancer 2026-04-16T17:10:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/city-of-hope-researchers-uncover-nat10-myc-pathway-driving-immunotherapy-resistance-in-colorectal-cancer 2026-04-16T17:10:39+00:00 hourly 0.9 https://trial.medpath.com/news/icer-calls-for-enhanced-transparency-in-fda-s-accelerated-approval-pathway 2026-04-16T17:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icer-calls-for-enhanced-transparency-in-fda-s-accelerated-approval-pathway 2026-04-16T17:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/latvian-study-reveals-77-long-term-cure-rate-for-multidrug-resistant-tuberculosis-far-exceeding-who-estimates 2026-04-16T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/latvian-study-reveals-77-long-term-cure-rate-for-multidrug-resistant-tuberculosis-far-exceeding-who-estimates 2026-04-16T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-reinstates-177-million-patent-verdict-for-teva-s-migraine-drug-ajovy-against-eli-lilly 2026-04-16T17:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-reinstates-177-million-patent-verdict-for-teva-s-migraine-drug-ajovy-against-eli-lilly 2026-04-16T17:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/elephas-biosciences-and-mithrl-combine-real-time-tumor-profiling-with-ai-to-advance-immunotherapy-response-prediction 2026-04-16T17:06:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elephas-biosciences-and-mithrl-combine-real-time-tumor-profiling-with-ai-to-advance-immunotherapy-response-prediction 2026-04-16T17:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/revolune-launches-multiplex-immunofluorescence-reagents-partners-with-mindpeak-for-ai-powered-spatial-biology-workflow 2026-04-16T17:06:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolune-launches-multiplex-immunofluorescence-reagents-partners-with-mindpeak-for-ai-powered-spatial-biology-workflow 2026-04-16T17:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/zyus-life-sciences-completes-phase-2a-utopia-1-trial-for-novel-non-opioid-cancer-pain-treatment 2026-04-16T17:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zyus-life-sciences-completes-phase-2a-utopia-1-trial-for-novel-non-opioid-cancer-pain-treatment 2026-04-16T17:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/achieve-life-sciences-secures-354-million-funding-for-cytisinicline-development-as-fda-review-continues 2026-04-16T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/achieve-life-sciences-secures-354-million-funding-for-cytisinicline-development-as-fda-review-continues 2026-04-16T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/roche-acquires-saga-diagnostics-for-595m-to-enhance-foundation-medicine-s-cancer-monitoring-portfolio 2026-04-16T17:04:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-acquires-saga-diagnostics-for-595m-to-enhance-foundation-medicine-s-cancer-monitoring-portfolio 2026-04-16T17:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/mytomorrows-and-rare-disease-research-partner-to-streamline-clinical-trial-access-for-rare-disease-patients 2026-04-16T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mytomorrows-and-rare-disease-research-partner-to-streamline-clinical-trial-access-for-rare-disease-patients 2026-04-16T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/panthera-biopartners-expands-european-clinical-trial-network-with-hungarian-acquisition 2026-04-16T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panthera-biopartners-expands-european-clinical-trial-network-with-hungarian-acquisition 2026-04-16T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/alethio-therapeutics-unveils-atx-011-first-in-class-mutation-agnostic-antibody-for-essential-thrombocythemia-treatment 2026-04-16T13:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alethio-therapeutics-unveils-atx-011-first-in-class-mutation-agnostic-antibody-for-essential-thrombocythemia-treatment 2026-04-16T13:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/medera-receives-fda-fast-track-designation-for-gene-therapy-targeting-duchenne-muscular-dystrophy-associated-cardiomyopathy 2026-04-16T13:06:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medera-receives-fda-fast-track-designation-for-gene-therapy-targeting-duchenne-muscular-dystrophy-associated-cardiomyopathy 2026-04-16T13:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/freya-biosciences-reports-positive-phase-1-results-for-fb301-in-ivf-related-embryo-implantation-failure 2026-04-16T13:05:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/freya-biosciences-reports-positive-phase-1-results-for-fb301-in-ivf-related-embryo-implantation-failure 2026-04-16T13:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/trabectedin-irinotecan-combination-shows-promise-against-ews-fli1-fusion-in-ewing-sarcoma-phase-1-2-trial 2026-04-16T13:05:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trabectedin-irinotecan-combination-shows-promise-against-ews-fli1-fusion-in-ewing-sarcoma-phase-1-2-trial 2026-04-16T13:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/scirent-appoints-cardiac-electrophysiology-expert-prof-dr-wilhelm-haverkamp-as-chief-medical-officer 2026-04-16T13:04:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scirent-appoints-cardiac-electrophysiology-expert-prof-dr-wilhelm-haverkamp-as-chief-medical-officer 2026-04-16T13:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-s-theranym-biologics-expands-msd-partnership-with-175-million-mammalian-manufacturing-facility 2026-04-16T13:04:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurobindo-pharma-s-theranym-biologics-expands-msd-partnership-with-175-million-mammalian-manufacturing-facility 2026-04-16T13:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-recalls-xanax-xr-3mg-tablets-nationwide-due-to-dissolution-failure 2026-04-16T09:05:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-recalls-xanax-xr-3mg-tablets-nationwide-due-to-dissolution-failure 2026-04-16T09:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/storm-therapeutics-secures-56m-series-c-to-advance-first-in-class-mettl3-inhibitor-stc-15-in-phase-ii-sarcoma-trial 2026-04-16T09:04:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/storm-therapeutics-secures-56m-series-c-to-advance-first-in-class-mettl3-inhibitor-stc-15-in-phase-ii-sarcoma-trial 2026-04-16T09:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-showcases-next-generation-adc-and-t-cell-engager-data-at-asco-2026 2026-04-16T09:04:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-showcases-next-generation-adc-and-t-cell-engager-data-at-asco-2026 2026-04-16T09:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-achieves-global-first-with-nmpa-acceptance-of-novel-lilrb4-cd3-bispecific-antibody-for-blood-cancers 2026-04-16T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabwell-achieves-global-first-with-nmpa-acceptance-of-novel-lilrb4-cd3-bispecific-antibody-for-blood-cancers 2026-04-16T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-review-confirms-alzheimer-s-amyloid-targeting-antibodies-show-minimal-clinical-benefit-despite-plaque-clearance 2026-04-16T09:04:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-review-confirms-alzheimer-s-amyloid-targeting-antibodies-show-minimal-clinical-benefit-despite-plaque-clearance 2026-04-16T09:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/diakonos-oncology-s-experimental-immunotherapy-shows-90-survival-improvement-in-glioblastoma-phase-i-trial 2026-04-16T05:04:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diakonos-oncology-s-experimental-immunotherapy-shows-90-survival-improvement-in-glioblastoma-phase-i-trial 2026-04-16T05:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-nmpa-accepts-mabwell-s-supplemental-application-for-denosumab-biosimilar-maiweijian-to-prevent-skeletal-events-in-cancer-patients 2026-04-16T05:03:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-nmpa-accepts-mabwell-s-supplemental-application-for-denosumab-biosimilar-maiweijian-to-prevent-skeletal-events-in-cancer-patients 2026-04-16T05:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/orvida-pharma-reports-positive-phase-1a-safety-data-for-km-023-first-in-class-trpv3-inhibitor-for-olmsted-syndrome 2026-04-16T01:06:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orvida-pharma-reports-positive-phase-1a-safety-data-for-km-023-first-in-class-trpv3-inhibitor-for-olmsted-syndrome 2026-04-16T01:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/elion-therapeutics-initiates-phase-2-trial-of-turletricin-for-invasive-mould-infections 2026-04-16T01:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elion-therapeutics-initiates-phase-2-trial-of-turletricin-for-invasive-mould-infections 2026-04-16T01:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/clearnote-health-s-avantect-pancreatic-cancer-test-achieves-82-6-sensitivity-in-early-detection 2026-04-16T01:05:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clearnote-health-s-avantect-pancreatic-cancer-test-achieves-82-6-sensitivity-in-early-detection 2026-04-16T01:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/alivecor-receives-ce-mark-for-portable-12-lead-ecg-system-with-ai-powered-cardiac-detection 2026-04-16T01:03:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alivecor-receives-ce-mark-for-portable-12-lead-ecg-system-with-ai-powered-cardiac-detection 2026-04-16T01:03:29+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-in-pact-av-drug-coated-balloon-shows-sustained-real-world-efficacy-in-dialysis-patients 2026-04-16T01:03:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-s-in-pact-av-drug-coated-balloon-shows-sustained-real-world-efficacy-in-dialysis-patients 2026-04-16T01:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/biologics-show-lower-ocular-disease-risk-in-psoriasis-patients-compared-to-conventional-therapies 2026-04-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biologics-show-lower-ocular-disease-risk-in-psoriasis-patients-compared-to-conventional-therapies 2026-04-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/replimune-lays-off-200-employees-following-second-fda-rejection-of-melanoma-treatment-rp1 2026-04-15T23:26:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/replimune-lays-off-200-employees-following-second-fda-rejection-of-melanoma-treatment-rp1 2026-04-15T23:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/pds-biotech-s-immunocytokine-adc-shows-78-response-rate-in-colorectal-cancer-trial 2026-04-15T23:22:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pds-biotech-s-immunocytokine-adc-shows-78-response-rate-in-colorectal-cancer-trial 2026-04-15T23:22:17+00:00 hourly 0.9 https://trial.medpath.com/news/cms-proposes-to-eliminate-alternative-payment-pathway-for-breakthrough-medical-devices 2026-04-15T23:22:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-proposes-to-eliminate-alternative-payment-pathway-for-breakthrough-medical-devices 2026-04-15T23:22:11+00:00 hourly 0.9 https://trial.medpath.com/news/litmys-and-konovo-form-strategic-partnership-to-transform-drug-development-intelligence 2026-04-15T17:11:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/litmys-and-konovo-form-strategic-partnership-to-transform-drug-development-intelligence 2026-04-15T17:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/dutch-drup-trial-demonstrates-significant-potential-for-off-label-cancer-drug-use-in-advanced-patients 2026-04-15T17:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dutch-drup-trial-demonstrates-significant-potential-for-off-label-cancer-drug-use-in-advanced-patients 2026-04-15T17:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/oncohost-unveils-proteomic-aging-biomarkers-for-immunotherapy-response-prediction-at-aacr-2026 2026-04-15T17:06:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncohost-unveils-proteomic-aging-biomarkers-for-immunotherapy-response-prediction-at-aacr-2026 2026-04-15T17:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/filana-therapeutics-simufilam-shows-dose-dependent-seizure-reduction-in-tuberous-sclerosis-complex-mouse-model 2026-04-15T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/filana-therapeutics-simufilam-shows-dose-dependent-seizure-reduction-in-tuberous-sclerosis-complex-mouse-model 2026-04-15T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/nucleai-and-sirona-dx-form-strategic-partnership-to-advance-spatial-proteomics-in-drug-development 2026-04-15T17:05:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nucleai-and-sirona-dx-form-strategic-partnership-to-advance-spatial-proteomics-in-drug-development 2026-04-15T17:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/sanyou-bio-launches-14-day-antibody-discovery-workflow-compressing-lead-molecule-identification-from-months-to-two-weeks 2026-04-15T17:05:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanyou-bio-launches-14-day-antibody-discovery-workflow-compressing-lead-molecule-identification-from-months-to-two-weeks 2026-04-15T17:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/penn-state-launches-phase-ii-trial-of-dfmo-for-pediatric-bone-cancers-following-fda-approval-in-neuroblastoma 2026-04-15T17:05:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penn-state-launches-phase-ii-trial-of-dfmo-for-pediatric-bone-cancers-following-fda-approval-in-neuroblastoma 2026-04-15T17:05:19+00:00 hourly 0.9 https://trial.medpath.com/news/fifty-1-labs-advances-ai-powered-peptide-biotechnology-platform-targeting-musculoskeletal-health 2026-04-15T17:04:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fifty-1-labs-advances-ai-powered-peptide-biotechnology-platform-targeting-musculoskeletal-health 2026-04-15T17:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-rapiblyk-for-pediatric-supraventricular-tachycardia-marking-first-u-s-treatment-option 2026-04-15T17:04:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-rapiblyk-for-pediatric-supraventricular-tachycardia-marking-first-u-s-treatment-option 2026-04-15T17:04:39+00:00 hourly 0.9 https://trial.medpath.com/news/biognosys-partners-with-michael-j-fox-foundation-to-develop-critical-lrrk2-biomarker-assays-for-parkinson-s-disease 2026-04-15T17:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biognosys-partners-with-michael-j-fox-foundation-to-develop-critical-lrrk2-biomarker-assays-for-parkinson-s-disease 2026-04-15T17:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/beeline-medicines-emerges-with-300m-series-a-and-bristol-myers-immune-disease-pipeline 2026-04-15T17:03:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beeline-medicines-emerges-with-300m-series-a-and-bristol-myers-immune-disease-pipeline 2026-04-15T17:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/proteomic-blood-test-predicts-kidney-failure-in-apol1-high-risk-individuals-years-before-symptoms-emerge 2026-04-15T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proteomic-blood-test-predicts-kidney-failure-in-apol1-high-risk-individuals-years-before-symptoms-emerge 2026-04-15T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/atelerix-expands-hydrogel-cell-preservation-technology-through-middle-east-partnership-and-new-organoid-solution 2026-04-15T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atelerix-expands-hydrogel-cell-preservation-technology-through-middle-east-partnership-and-new-organoid-solution 2026-04-15T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/labcorp-launches-first-fda-cleared-rapid-fentanyl-test-made-in-us-delivers-results-in-10-minutes 2026-04-15T13:10:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labcorp-launches-first-fda-cleared-rapid-fentanyl-test-made-in-us-delivers-results-in-10-minutes 2026-04-15T13:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/arbutus-receives-fda-fast-track-designation-for-hepatitis-b-rnai-therapeutic-imdusiran 2026-04-15T13:10:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arbutus-receives-fda-fast-track-designation-for-hepatitis-b-rnai-therapeutic-imdusiran 2026-04-15T13:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/c-mo-medical-solutions-receives-ce-mark-for-ai-powered-cough-monitoring-system 2026-04-15T13:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/c-mo-medical-solutions-receives-ce-mark-for-ai-powered-cough-monitoring-system 2026-04-15T13:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/yellowbird-diagnostics-initiates-first-in-human-trial-of-novel-inflammation-imaging-agent-neucavis 2026-04-15T13:09:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yellowbird-diagnostics-initiates-first-in-human-trial-of-novel-inflammation-imaging-agent-neucavis 2026-04-15T13:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-invests-in-restore-vision-s-gene-therapy-for-retinal-blindness-through-first-cvc-deal 2026-04-15T13:09:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-invests-in-restore-vision-s-gene-therapy-for-retinal-blindness-through-first-cvc-deal 2026-04-15T13:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/two-phase-2-trials-fail-to-demonstrate-cognitive-benefits-in-schizophrenia-despite-different-mechanisms 2026-04-15T13:08:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-phase-2-trials-fail-to-demonstrate-cognitive-benefits-in-schizophrenia-despite-different-mechanisms 2026-04-15T13:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/isofol-medical-expands-phase-ib-ii-trial-for-arfolitixorin-in-colorectal-cancer-following-german-regulatory-approval 2026-04-15T13:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isofol-medical-expands-phase-ib-ii-trial-for-arfolitixorin-in-colorectal-cancer-following-german-regulatory-approval 2026-04-15T13:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/synusight-s-sst001-a-synuclein-pet-tracer-receives-nmpa-approval-for-phase-i-clinical-trial-in-china 2026-04-15T05:04:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synusight-s-sst001-a-synuclein-pet-tracer-receives-nmpa-approval-for-phase-i-clinical-trial-in-china 2026-04-15T05:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-draft-guidance-on-next-generation-sequencing-for-gene-therapy-safety-assessment 2026-04-15T01:04:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-draft-guidance-on-next-generation-sequencing-for-gene-therapy-safety-assessment 2026-04-15T01:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-suzhou-biosafety-testing-center-earns-fourth-ema-gmp-certification-enabling-19-biologics-for-eu-market 2026-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuxi-biologics-suzhou-biosafety-testing-center-earns-fourth-ema-gmp-certification-enabling-19-biologics-for-eu-market 2026-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vasa-therapeutics-partners-with-lilly-tunelab-to-accelerate-ai-driven-camkii-inhibitor-development 2026-04-14T21:12:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vasa-therapeutics-partners-with-lilly-tunelab-to-accelerate-ai-driven-camkii-inhibitor-development 2026-04-14T21:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/toby-s-urine-based-multi-cancer-detection-test-receives-fda-breakthrough-device-designation 2026-04-14T21:12:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/toby-s-urine-based-multi-cancer-detection-test-receives-fda-breakthrough-device-designation 2026-04-14T21:12:37+00:00 hourly 0.9 https://trial.medpath.com/news/impact-biotech-reports-promising-early-results-for-padeliporfin-vtp-in-pancreatic-cancer-eyes-strategic-partnerships 2026-04-14T21:11:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/impact-biotech-reports-promising-early-results-for-padeliporfin-vtp-in-pancreatic-cancer-eyes-strategic-partnerships 2026-04-14T21:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/lantern-pharma-launches-withzeta-ai-world-s-first-multi-agentic-ai-co-scientist-for-rare-cancer-drug-discovery 2026-04-14T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantern-pharma-launches-withzeta-ai-world-s-first-multi-agentic-ai-co-scientist-for-rare-cancer-drug-discovery 2026-04-14T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/obsidian-and-galera-therapeutics-announce-350-million-merger-to-advance-next-generation-til-cell-therapy 2026-04-14T21:10:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obsidian-and-galera-therapeutics-announce-350-million-merger-to-advance-next-generation-til-cell-therapy 2026-04-14T21:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/rivus-pharmaceuticals-initiates-phase-ii-amplify-trial-for-hu6-in-mash-treatment 2026-04-14T21:10:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rivus-pharmaceuticals-initiates-phase-ii-amplify-trial-for-hu6-in-mash-treatment 2026-04-14T21:10:30+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-acquires-crossbridge-bio-for-up-to-300-million-to-advance-dual-payload-adc-technology 2026-04-14T21:10:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-acquires-crossbridge-bio-for-up-to-300-million-to-advance-dual-payload-adc-technology 2026-04-14T21:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/hinge-bio-initiates-first-in-human-trial-of-hb2198-novel-dual-target-b-cell-depleting-therapy-for-autoimmune-diseases 2026-04-14T21:10:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hinge-bio-initiates-first-in-human-trial-of-hb2198-novel-dual-target-b-cell-depleting-therapy-for-autoimmune-diseases 2026-04-14T21:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/phrontline-biopharma-s-tj106-shows-promise-against-her2-low-and-adc-resistant-tumors-in-preclinical-studies 2026-04-14T21:09:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phrontline-biopharma-s-tj106-shows-promise-against-her2-low-and-adc-resistant-tumors-in-preclinical-studies 2026-04-14T21:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/vectorbuilder-launches-mutefree-aav-technology-to-solve-itr-instability-in-gene-therapy-manufacturing 2026-04-14T21:05:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vectorbuilder-launches-mutefree-aav-technology-to-solve-itr-instability-in-gene-therapy-manufacturing 2026-04-14T21:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-experience-with-revakinagene-taroretcel-lwey-encelto-for-mactel-first-year-insights-on-patient-selection-and-surgical-technique 2026-04-14T21:03:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-experience-with-revakinagene-taroretcel-lwey-encelto-for-mactel-first-year-insights-on-patient-selection-and-surgical-technique 2026-04-14T21:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/debiopharm-reports-first-clinical-data-from-mythic-trial-combining-wee1-and-pkmyt1-inhibitors-at-aacr-2026 2026-04-14T21:03:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/debiopharm-reports-first-clinical-data-from-mythic-trial-combining-wee1-and-pkmyt1-inhibitors-at-aacr-2026 2026-04-14T21:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/medline-recalls-angiographic-syringes-after-fda-warning-over-life-threatening-disconnection-risk 2026-04-14T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medline-recalls-angiographic-syringes-after-fda-warning-over-life-threatening-disconnection-risk 2026-04-14T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/hibercell-s-hc-7366-shows-promise-in-late-line-renal-cell-carcinoma-with-37-response-rate-in-phase-1b-trial 2026-04-14T14:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hibercell-s-hc-7366-shows-promise-in-late-line-renal-cell-carcinoma-with-37-response-rate-in-phase-1b-trial 2026-04-14T14:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/single-cell-analysis-reveals-immune-dynamics-of-moderna-covid-19-vaccine-in-pregnant-women 2026-04-14T13:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-cell-analysis-reveals-immune-dynamics-of-moderna-covid-19-vaccine-in-pregnant-women 2026-04-14T13:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/birmingham-receives-ps10m-to-build-advanced-biomanufacturing-facility-for-cell-and-gene-therapies 2026-04-14T13:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/birmingham-receives-ps10m-to-build-advanced-biomanufacturing-facility-for-cell-and-gene-therapies 2026-04-14T13:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/hainan-s-boao-lecheng-pilot-zone-slashes-drug-approval-to-1-6-days-transforming-rare-disease-access 2026-04-14T13:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hainan-s-boao-lecheng-pilot-zone-slashes-drug-approval-to-1-6-days-transforming-rare-disease-access 2026-04-14T13:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-guidance-and-regulatory-uncertainty-create-challenges-for-us-biosimilar-market-development 2026-04-14T13:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-guidance-and-regulatory-uncertainty-create-challenges-for-us-biosimilar-market-development 2026-04-14T13:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/adcendo-secures-75-million-series-c-to-advance-first-in-class-adc-pipeline-for-high-unmet-need-cancers 2026-04-14T13:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adcendo-secures-75-million-series-c-to-advance-first-in-class-adc-pipeline-for-high-unmet-need-cancers 2026-04-14T13:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/huons-biopharma-secures-kuwait-approval-for-hutox-botulinum-toxin-accelerates-middle-east-expansion 2026-04-14T13:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huons-biopharma-secures-kuwait-approval-for-hutox-botulinum-toxin-accelerates-middle-east-expansion 2026-04-14T13:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/artcline-completes-patient-recruitment-for-septic-shock-immune-cell-therapy-trial 2026-04-14T13:06:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artcline-completes-patient-recruitment-for-septic-shock-immune-cell-therapy-trial 2026-04-14T13:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/memorial-health-joins-national-clinical-trial-testing-advanced-feeding-tube-system-for-premature-infants 2026-04-14T10:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/memorial-health-joins-national-clinical-trial-testing-advanced-feeding-tube-system-for-premature-infants 2026-04-14T10:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/asgard-therapeutics-appoints-veteran-oncologist-as-cmo-to-advance-novel-cancer-immunotherapy-at-108 2026-04-14T09:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asgard-therapeutics-appoints-veteran-oncologist-as-cmo-to-advance-novel-cancer-immunotherapy-at-108 2026-04-14T09:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/panntherapi-advances-phase-2a-trial-for-rare-epilepsy-drug-pti5803-targeting-pannexin-1-channel 2026-04-14T09:05:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panntherapi-advances-phase-2a-trial-for-rare-epilepsy-drug-pti5803-targeting-pannexin-1-channel 2026-04-14T09:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/ailux-appoints-former-astrazeneca-executive-maria-belvisi-as-chief-scientific-officer-to-lead-drug-development-strategy 2026-04-14T09:04:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ailux-appoints-former-astrazeneca-executive-maria-belvisi-as-chief-scientific-officer-to-lead-drug-development-strategy 2026-04-14T09:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-daretabart-for-high-risk-neuroblastoma-treatment 2026-04-14T09:04:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-daretabart-for-high-risk-neuroblastoma-treatment 2026-04-14T09:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/protaryx-medical-receives-fda-510-k-clearance-for-transseptal-puncture-device 2026-04-14T05:06:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protaryx-medical-receives-fda-510-k-clearance-for-transseptal-puncture-device 2026-04-14T05:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/eclipse-life-sciences-completes-enrollment-in-phase-2-trial-of-ec-104-for-diabetic-macular-edema 2026-04-14T01:11:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eclipse-life-sciences-completes-enrollment-in-phase-2-trial-of-ec-104-for-diabetic-macular-edema 2026-04-14T01:11:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-2200-notices-to-companies-and-researchers-over-unpublished-clinical-trial-results 2026-04-14T01:10:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-2200-notices-to-companies-and-researchers-over-unpublished-clinical-trial-results 2026-04-14T01:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/scripps-health-receives-12-7-million-grant-to-develop-scaffold-free-stem-cell-therapy-for-knee-cartilage-repair 2026-04-14T01:10:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scripps-health-receives-12-7-million-grant-to-develop-scaffold-free-stem-cell-therapy-for-knee-cartilage-repair 2026-04-14T01:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/veld-pharmaceuticals-partners-with-chiesi-to-launch-rare-disease-access-program-across-africa 2026-04-14T01:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veld-pharmaceuticals-partners-with-chiesi-to-launch-rare-disease-access-program-across-africa 2026-04-14T01:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/maryland-sets-first-drug-price-cap-on-diabetes-medication-jardiance-at-204-per-month 2026-04-13T21:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maryland-sets-first-drug-price-cap-on-diabetes-medication-jardiance-at-204-per-month 2026-04-13T21:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/bioora-partners-with-cincinnati-children-s-to-advance-next-generation-car-t-therapy-for-pediatric-leukemia 2026-04-13T21:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioora-partners-with-cincinnati-children-s-to-advance-next-generation-car-t-therapy-for-pediatric-leukemia 2026-04-13T21:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-trastuzumab-deruxtecan-improves-five-year-survival-in-her2-positive-metastatic-colorectal-cancer 2026-04-13T21:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-shows-trastuzumab-deruxtecan-improves-five-year-survival-in-her2-positive-metastatic-colorectal-cancer 2026-04-13T21:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/ohsu-receives-9-2-million-nih-funding-to-develop-advanced-organs-on-chips-for-bone-cancer-research 2026-04-13T21:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ohsu-receives-9-2-million-nih-funding-to-develop-advanced-organs-on-chips-for-bone-cancer-research 2026-04-13T21:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-secures-745m-licensing-deal-with-haisco-for-pain-pipeline-assets 2026-04-13T21:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-secures-745m-licensing-deal-with-haisco-for-pain-pipeline-assets 2026-04-13T21:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/airway-therapeutics-strengthens-board-with-cormedix-ceo-joe-todisco-as-zelpultide-alfa-advances 2026-04-13T21:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/airway-therapeutics-strengthens-board-with-cormedix-ceo-joe-todisco-as-zelpultide-alfa-advances 2026-04-13T21:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/nih-sponsored-trial-shows-stent-placement-significantly-reduces-post-thrombotic-syndrome-severity 2026-04-13T17:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-sponsored-trial-shows-stent-placement-significantly-reduces-post-thrombotic-syndrome-severity 2026-04-13T17:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/frontier-medicines-appoints-former-seagen-ceo-david-epstein-to-board-as-company-advances-covalent-precision-medicine-pipeline 2026-04-13T17:04:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/frontier-medicines-appoints-former-seagen-ceo-david-epstein-to-board-as-company-advances-covalent-precision-medicine-pipeline 2026-04-13T17:04:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-plans-reclassification-of-diagnostic-endoscopic-light-source-systems-used-in-bladder-cancer-detection 2026-04-13T17:04:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-plans-reclassification-of-diagnostic-endoscopic-light-source-systems-used-in-bladder-cancer-detection 2026-04-13T17:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/akebia-therapeutics-initiates-phase-1-trial-of-akb-9090-for-cardiac-surgery-associated-acute-kidney-injury 2026-04-13T17:04:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akebia-therapeutics-initiates-phase-1-trial-of-akb-9090-for-cardiac-surgery-associated-acute-kidney-injury 2026-04-13T17:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/norwegian-oslo-patient-achieves-hiv-remission-following-stem-cell-transplant-with-rare-genetic-mutation 2026-04-13T15:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/norwegian-oslo-patient-achieves-hiv-remission-following-stem-cell-transplant-with-rare-genetic-mutation 2026-04-13T15:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/prosomnus-receives-fda-clearance-for-first-theragnostic-sleep-apnea-device-combining-oral-therapy-with-continuous-monitoring 2026-04-13T13:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prosomnus-receives-fda-clearance-for-first-theragnostic-sleep-apnea-device-combining-oral-therapy-with-continuous-monitoring 2026-04-13T13:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/korea-university-moderna-mrna-hantavirus-vaccine-stalls-as-funding-shortfall-blocks-clinical-trials 2026-04-13T13:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korea-university-moderna-mrna-hantavirus-vaccine-stalls-as-funding-shortfall-blocks-clinical-trials 2026-04-13T13:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/duke-university-clinical-trial-shows-promise-for-immunotherapy-as-first-line-treatment-in-colorectal-cancer 2026-04-13T13:07:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duke-university-clinical-trial-shows-promise-for-immunotherapy-as-first-line-treatment-in-colorectal-cancer 2026-04-13T13:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/haisco-partners-with-abbvie-in-745-million-pain-therapy-licensing-deal 2026-04-13T13:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/haisco-partners-with-abbvie-in-745-million-pain-therapy-licensing-deal 2026-04-13T13:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/os-therapies-strengthens-strategic-advisory-board-with-industry-luminaries-craig-eagle-and-robert-langer 2026-04-13T13:05:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/os-therapies-strengthens-strategic-advisory-board-with-industry-luminaries-craig-eagle-and-robert-langer 2026-04-13T13:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/spyre-therapeutics-spy001-demonstrates-promising-efficacy-in-phase-2-ulcerative-colitis-trial 2026-04-13T13:03:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spyre-therapeutics-spy001-demonstrates-promising-efficacy-in-phase-2-ulcerative-colitis-trial 2026-04-13T13:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/roche-receives-ce-mark-for-elecsys-nfl-blood-test-to-monitor-multiple-sclerosis-neuroinflammation 2026-04-13T13:03:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-receives-ce-mark-for-elecsys-nfl-blood-test-to-monitor-multiple-sclerosis-neuroinflammation 2026-04-13T13:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/acucort-reaches-fda-agreement-on-pediatric-study-plan-for-zeqmelit-r-clearing-path-toward-us-nda-submission 2026-04-13T09:04:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acucort-reaches-fda-agreement-on-pediatric-study-plan-for-zeqmelit-r-clearing-path-toward-us-nda-submission 2026-04-13T09:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/synox-therapeutics-reports-positive-phase-3-results-for-emactuzumab-in-tenosynovial-giant-cell-tumor 2026-04-13T09:04:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synox-therapeutics-reports-positive-phase-3-results-for-emactuzumab-in-tenosynovial-giant-cell-tumor 2026-04-13T09:04:19+00:00 hourly 0.9 https://trial.medpath.com/news/st-pharm-secures-first-japanese-patent-for-mrna-lnp-platform-technology-stp1244 2026-04-13T05:05:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/st-pharm-secures-first-japanese-patent-for-mrna-lnp-platform-technology-stp1244 2026-04-13T05:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/hlb-life-science-r-d-secures-two-major-government-r-d-projects-worth-6-2-million-for-ai-oncology-and-medical-cannabis-development 2026-04-13T05:05:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hlb-life-science-r-d-secures-two-major-government-r-d-projects-worth-6-2-million-for-ai-oncology-and-medical-cannabis-development 2026-04-13T05:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/yuhan-s-yh35995-receives-fda-orphan-drug-designation-for-gaucher-disease-treatment 2026-04-13T05:05:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yuhan-s-yh35995-receives-fda-orphan-drug-designation-for-gaucher-disease-treatment 2026-04-13T05:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/zeto-receives-fda-clearance-for-new-wave-eeg-system-to-address-outpatient-neurodiagnostic-delays 2026-04-13T05:04:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeto-receives-fda-clearance-for-new-wave-eeg-system-to-address-outpatient-neurodiagnostic-delays 2026-04-13T05:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/telix-and-regeneron-form-2-1-billion-strategic-partnership-to-develop-next-generation-radiopharmaceuticals 2026-04-13T01:03:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telix-and-regeneron-form-2-1-billion-strategic-partnership-to-develop-next-generation-radiopharmaceuticals 2026-04-13T01:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/novel-b7h3-antibody-drug-conjugate-shows-strong-efficacy-in-cervical-and-ovarian-cancers 2026-04-13T01:03:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-b7h3-antibody-drug-conjugate-shows-strong-efficacy-in-cervical-and-ovarian-cancers 2026-04-13T01:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/miracell-receives-fda-510-k-clearance-for-smart-m-cell-stem-cell-extraction-system 2026-04-12T21:03:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/miracell-receives-fda-510-k-clearance-for-smart-m-cell-stem-cell-extraction-system 2026-04-12T21:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-nanodisc-platform-reveals-hidden-viral-vulnerabilities-for-hiv-and-ebola-vaccine-development 2026-04-12T17:04:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-nanodisc-platform-reveals-hidden-viral-vulnerabilities-for-hiv-and-ebola-vaccine-development 2026-04-12T17:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/rapid-diagnostic-testing-and-new-antibiotics-fail-to-reduce-deaths-from-drug-resistant-infections 2026-04-12T14:33:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapid-diagnostic-testing-and-new-antibiotics-fail-to-reduce-deaths-from-drug-resistant-infections 2026-04-12T14:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-discontinues-brensocatib-development-for-hidradenitis-suppurativa-after-phase-2b-trial-failure 2026-04-11T21:05:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insmed-discontinues-brensocatib-development-for-hidradenitis-suppurativa-after-phase-2b-trial-failure 2026-04-11T21:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/cartherics-expands-catalent-partnership-and-secures-japanese-patent-for-off-the-shelf-car-nk-cell-therapies 2026-04-11T21:05:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cartherics-expands-catalent-partnership-and-secures-japanese-patent-for-off-the-shelf-car-nk-cell-therapies 2026-04-11T21:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/alligator-bioscience-partners-with-unicancer-to-explore-phase-3-trial-for-pancreatic-cancer-drug-mitazalimab 2026-04-11T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alligator-bioscience-partners-with-unicancer-to-explore-phase-3-trial-for-pancreatic-cancer-drug-mitazalimab 2026-04-11T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/letrozole-shows-promise-in-improving-ivf-success-rates-for-poor-ovarian-responders 2026-04-11T17:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/letrozole-shows-promise-in-improving-ivf-success-rates-for-poor-ovarian-responders 2026-04-11T17:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/hanx-biopharmaceuticals-presents-four-innovative-cancer-therapies-at-2026-aacr-annual-meeting 2026-04-11T09:04:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hanx-biopharmaceuticals-presents-four-innovative-cancer-therapies-at-2026-aacr-annual-meeting 2026-04-11T09:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/korea-university-and-mfc-partner-to-develop-muscle-loss-therapeutics-for-space-missions 2026-04-11T09:03:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korea-university-and-mfc-partner-to-develop-muscle-loss-therapeutics-for-space-missions 2026-04-11T09:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/hemab-therapeutics-files-for-nasdaq-ipo-to-advance-bleeding-disorder-therapies 2026-04-11T01:03:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemab-therapeutics-files-for-nasdaq-ipo-to-advance-bleeding-disorder-therapies 2026-04-11T01:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-pharmaceuticals-launches-generic-bimatoprost-for-glaucoma-treatment 2026-04-10T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-pharmaceuticals-launches-generic-bimatoprost-for-glaucoma-treatment 2026-04-10T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/three-novel-therapies-target-frail-hnscc-patients-unable-to-tolerate-standard-treatment 2026-04-10T21:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-novel-therapies-target-frail-hnscc-patients-unable-to-tolerate-standard-treatment 2026-04-10T21:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/vivatides-therapeutics-raises-54-million-series-a-to-advance-extrahepatic-rna-therapeutics-platform 2026-04-10T21:09:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivatides-therapeutics-raises-54-million-series-a-to-advance-extrahepatic-rna-therapeutics-platform 2026-04-10T21:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/sylvester-cancer-center-tests-novel-virus-immunotherapy-combination-for-aggressive-neuroendocrine-tumors 2026-04-10T21:06:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sylvester-cancer-center-tests-novel-virus-immunotherapy-combination-for-aggressive-neuroendocrine-tumors 2026-04-10T21:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trials-as-a-pathway-not-a-last-resort-the-evolving-landscape-of-ovarian-cancer-research 2026-04-10T21:04:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trials-as-a-pathway-not-a-last-resort-the-evolving-landscape-of-ovarian-cancer-research 2026-04-10T21:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-pharmaceuticals-leverages-glp-1-manufacturing-partnership-with-pfizer-to-expand-beyond-traditional-generics 2026-04-10T21:04:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-pharmaceuticals-leverages-glp-1-manufacturing-partnership-with-pfizer-to-expand-beyond-traditional-generics 2026-04-10T21:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/canada-invests-50-million-to-build-critical-medicines-production-centre-in-alberta 2026-04-10T17:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-invests-50-million-to-build-critical-medicines-production-centre-in-alberta 2026-04-10T17:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/ai-analysis-of-reddit-posts-reveals-unreported-glp-1-drug-side-effects-including-reproductive-and-temperature-symptoms 2026-04-10T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-analysis-of-reddit-posts-reveals-unreported-glp-1-drug-side-effects-including-reproductive-and-temperature-symptoms 2026-04-10T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/iaso-bio-partners-with-instituto-butantan-to-bring-car-t-cell-therapy-to-brazil-s-public-health-system 2026-04-10T17:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iaso-bio-partners-with-instituto-butantan-to-bring-car-t-cell-therapy-to-brazil-s-public-health-system 2026-04-10T17:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/yeast-beta-glucan-supplement-reprograms-bone-marrow-stem-cells-to-restore-anti-tumor-immunity-in-obesity 2026-04-10T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yeast-beta-glucan-supplement-reprograms-bone-marrow-stem-cells-to-restore-anti-tumor-immunity-in-obesity 2026-04-10T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/ema-issues-urgent-safety-alert-for-cenobamate-following-severe-liver-injury-reports 2026-04-10T17:04:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-issues-urgent-safety-alert-for-cenobamate-following-severe-liver-injury-reports 2026-04-10T17:04:59+00:00 hourly 0.9 https://trial.medpath.com/news/severe-enterocolitis-emerges-as-rare-but-fatal-complication-of-bcma-car-t-therapy 2026-04-10T17:04:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/severe-enterocolitis-emerges-as-rare-but-fatal-complication-of-bcma-car-t-therapy 2026-04-10T17:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/realta-secures-40m-to-advance-first-in-class-therapy-for-fatal-neonatal-brain-injury 2026-04-10T17:03:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/realta-secures-40m-to-advance-first-in-class-therapy-for-fatal-neonatal-brain-injury 2026-04-10T17:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/kura-oncology-to-present-updated-darlifarnib-combination-data-for-renal-cell-carcinoma-at-ikcs-europe-2026 2026-04-10T13:05:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kura-oncology-to-present-updated-darlifarnib-combination-data-for-renal-cell-carcinoma-at-ikcs-europe-2026 2026-04-10T13:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/ailsynbio-and-dong-e-e-jiao-partner-to-advance-ai-driven-traditional-chinese-medicine-research 2026-04-10T13:05:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ailsynbio-and-dong-e-e-jiao-partner-to-advance-ai-driven-traditional-chinese-medicine-research 2026-04-10T13:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-acting-director-delays-publication-of-study-showing-covid-19-vaccine-effectiveness 2026-04-10T13:05:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-acting-director-delays-publication-of-study-showing-covid-19-vaccine-effectiveness 2026-04-10T13:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-bispecific-antibody-tarlatamab-receives-china-approval-for-small-cell-lung-cancer 2026-04-10T13:04:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-bispecific-antibody-tarlatamab-receives-china-approval-for-small-cell-lung-cancer 2026-04-10T13:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/france-becomes-first-nation-to-approve-iv-ketamine-for-acute-suicidal-crisis 2026-04-10T13:04:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/france-becomes-first-nation-to-approve-iv-ketamine-for-acute-suicidal-crisis 2026-04-10T13:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/ascendis-pharma-completes-direct-listing-transition-on-nasdaq-exchanges-all-adss-for-ordinary-shares 2026-04-10T09:05:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascendis-pharma-completes-direct-listing-transition-on-nasdaq-exchanges-all-adss-for-ordinary-shares 2026-04-10T09:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/neuland-laboratories-appoints-new-ceo-and-managing-director 2026-04-10T05:05:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuland-laboratories-appoints-new-ceo-and-managing-director 2026-04-10T05:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/arkbio-initiates-first-in-human-trial-of-novel-long-acting-influenza-drug-ak0406-in-australia 2026-04-10T05:03:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arkbio-initiates-first-in-human-trial-of-novel-long-acting-influenza-drug-ak0406-in-australia 2026-04-10T05:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/premature-menopause-linked-to-40-higher-lifetime-risk-of-coronary-heart-disease-landmark-study-finds 2026-04-10T03:04:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/premature-menopause-linked-to-40-higher-lifetime-risk-of-coronary-heart-disease-landmark-study-finds 2026-04-10T03:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/allrock-bio-initiates-phase-iia-trial-of-first-in-class-oral-rock-inhibitor-for-pulmonary-hypertension 2026-04-10T01:06:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allrock-bio-initiates-phase-iia-trial-of-first-in-class-oral-rock-inhibitor-for-pulmonary-hypertension 2026-04-10T01:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/nextbiomedical-secures-exclusive-japan-distribution-deal-for-nexsphere-f-embolization-device 2026-04-10T01:06:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextbiomedical-secures-exclusive-japan-distribution-deal-for-nexsphere-f-embolization-device 2026-04-10T01:06:16+00:00 hourly 0.9 https://trial.medpath.com/news/nmg-secures-297-million-financing-package-to-advance-graphite-mining-operations-for-battery-materials 2026-04-10T01:05:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nmg-secures-297-million-financing-package-to-advance-graphite-mining-operations-for-battery-materials 2026-04-10T01:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-biotherapeutics-partners-with-bristol-myers-squibb-to-develop-next-generation-t-cell-engagers-for-solid-tumors 2026-04-09T21:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-biotherapeutics-partners-with-bristol-myers-squibb-to-develop-next-generation-t-cell-engagers-for-solid-tumors 2026-04-09T21:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-waterloo-study-shows-natural-compounds-enhance-alzheimer-s-antibody-therapies 2026-04-09T21:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-waterloo-study-shows-natural-compounds-enhance-alzheimer-s-antibody-therapies 2026-04-09T21:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/champions-oncology-to-present-eight-studies-on-predicting-cancer-drug-response-at-aacr-2026 2026-04-09T21:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/champions-oncology-to-present-eight-studies-on-predicting-cancer-drug-response-at-aacr-2026 2026-04-09T21:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/galenusrx-and-clutch-health-form-strategic-partnership-to-enhance-complex-patient-care-through-precision-medicine-and-behavioral-incentives 2026-04-09T21:06:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galenusrx-and-clutch-health-form-strategic-partnership-to-enhance-complex-patient-care-through-precision-medicine-and-behavioral-incentives 2026-04-09T21:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-biotech-achieves-hkex-milestone-with-b-marker-removal-advances-global-adc-pipeline 2026-04-09T21:06:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kelun-biotech-achieves-hkex-milestone-with-b-marker-removal-advances-global-adc-pipeline 2026-04-09T21:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/deepcyte-secures-1-5m-seed-funding-to-advance-ai-powered-single-cell-toxicology-platform 2026-04-09T21:06:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deepcyte-secures-1-5m-seed-funding-to-advance-ai-powered-single-cell-toxicology-platform 2026-04-09T21:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/covar-receives-darpa-contract-to-develop-ai-system-for-medical-decision-making-enhancement 2026-04-09T21:05:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covar-receives-darpa-contract-to-develop-ai-system-for-medical-decision-making-enhancement 2026-04-09T21:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/merck-discontinues-in-house-trop2-adc-mk-6837-after-revealing-dual-development-strategy 2026-04-09T21:04:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-discontinues-in-house-trop2-adc-mk-6837-after-revealing-dual-development-strategy 2026-04-09T21:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/click-therapeutics-secures-50m-series-d-to-commercialize-breakthrough-digital-therapeutic-for-schizophrenia 2026-04-09T17:14:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/click-therapeutics-secures-50m-series-d-to-commercialize-breakthrough-digital-therapeutic-for-schizophrenia 2026-04-09T17:14:04+00:00 hourly 0.9 https://trial.medpath.com/news/byondis-appoints-christoph-korpus-as-ceo-to-lead-adc-technology-platform-development 2026-04-09T17:13:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/byondis-appoints-christoph-korpus-as-ceo-to-lead-adc-technology-platform-development 2026-04-09T17:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/rani-therapeutics-strengthens-leadership-team-with-key-strategic-appointments-to-advance-oral-biologics-platform 2026-04-09T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rani-therapeutics-strengthens-leadership-team-with-key-strategic-appointments-to-advance-oral-biologics-platform 2026-04-09T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-receives-fda-approval-for-generic-progesterone-vaginal-inserts-in-59-2-million-market 2026-04-09T17:12:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-receives-fda-approval-for-generic-progesterone-vaginal-inserts-in-59-2-million-market 2026-04-09T17:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-acquires-market-authorization-for-nuvaxovid-covid-19-vaccine-in-canada 2026-04-09T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-acquires-market-authorization-for-nuvaxovid-covid-19-vaccine-in-canada 2026-04-09T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/oncoc4-initiates-first-in-class-anti-siglec-10-antibody-trial-for-alzheimer-s-disease-treatment 2026-04-09T17:07:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncoc4-initiates-first-in-class-anti-siglec-10-antibody-trial-for-alzheimer-s-disease-treatment 2026-04-09T17:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/granules-india-implements-digital-overhaul-following-fda-warning-over-manufacturing-violations 2026-04-09T17:07:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/granules-india-implements-digital-overhaul-following-fda-warning-over-manufacturing-violations 2026-04-09T17:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-achieves-world-first-simultaneous-remission-of-three-autoimmune-diseases 2026-04-09T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-achieves-world-first-simultaneous-remission-of-three-autoimmune-diseases 2026-04-09T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/alpheus-medical-launches-phase-2b-trial-for-novel-glioblastoma-therapy-using-ultrasound-activated-drug-approach 2026-04-09T17:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alpheus-medical-launches-phase-2b-trial-for-novel-glioblastoma-therapy-using-ultrasound-activated-drug-approach 2026-04-09T17:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/sparian-biosciences-initiates-phase-1-trial-of-sbs-147-novel-oral-pain-drug-targeting-opioid-alternative 2026-04-09T17:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sparian-biosciences-initiates-phase-1-trial-of-sbs-147-novel-oral-pain-drug-targeting-opioid-alternative 2026-04-09T17:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-and-seer-partner-with-singapore-s-precise-sg100k-for-large-scale-proteomics-study 2026-04-09T17:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-and-seer-partner-with-singapore-s-precise-sg100k-for-large-scale-proteomics-study 2026-04-09T17:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/boston-oncology-secures-100m-licensing-deal-for-chinese-cancer-drugs-in-middle-east-and-north-africa 2026-04-09T17:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-oncology-secures-100m-licensing-deal-for-chinese-cancer-drugs-in-middle-east-and-north-africa 2026-04-09T17:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-achieves-complete-remission-in-woman-with-three-simultaneous-autoimmune-diseases 2026-04-09T17:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-achieves-complete-remission-in-woman-with-three-simultaneous-autoimmune-diseases 2026-04-09T17:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/jazz-pharmaceuticals-presents-new-epidiolex-behavioral-data-at-aan-2026-demonstrating-impact-beyond-seizure-control 2026-04-09T17:05:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-presents-new-epidiolex-behavioral-data-at-aan-2026-demonstrating-impact-beyond-seizure-control 2026-04-09T17:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/cures-within-reach-funds-five-drug-repurposing-trials-in-chicago-to-address-unmet-medical-needs 2026-04-09T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cures-within-reach-funds-five-drug-repurposing-trials-in-chicago-to-address-unmet-medical-needs 2026-04-09T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-develops-brain-penetrating-aramchol-formulation-for-parkinson-s-disease-and-synucleinopathies 2026-04-09T17:04:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galmed-develops-brain-penetrating-aramchol-formulation-for-parkinson-s-disease-and-synucleinopathies 2026-04-09T17:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/verrica-s-vp-315-shows-promising-abscopal-effect-in-basal-cell-carcinoma-phase-2-trial 2026-04-09T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verrica-s-vp-315-shows-promising-abscopal-effect-in-basal-cell-carcinoma-phase-2-trial 2026-04-09T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/brd2-emerges-as-key-driver-of-bet-inhibitor-resistance-across-multiple-cancers 2026-04-09T13:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brd2-emerges-as-key-driver-of-bet-inhibitor-resistance-across-multiple-cancers 2026-04-09T13:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/c4-therapeutics-and-roche-expand-partnership-with-1-billion-dac-collaboration 2026-04-09T13:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/c4-therapeutics-and-roche-expand-partnership-with-1-billion-dac-collaboration 2026-04-09T13:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-exercises-option-for-kymera-s-kt-200-cdk2-degrader-triggering-45m-milestone-payment 2026-04-09T13:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-exercises-option-for-kymera-s-kt-200-cdk2-degrader-triggering-45m-milestone-payment 2026-04-09T13:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/bdc-launches-150-million-life-sciences-venture-fund-to-address-early-stage-funding-gap-in-canada 2026-04-09T13:06:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bdc-launches-150-million-life-sciences-venture-fund-to-address-early-stage-funding-gap-in-canada 2026-04-09T13:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-car-t-therapy-for-solid-tumors-set-to-launch-in-china 2026-04-09T09:05:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-first-car-t-therapy-for-solid-tumors-set-to-launch-in-china 2026-04-09T09:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/sbp-group-s-m701-bispecific-antibody-receives-nda-acceptance-for-malignant-ascites-treatment 2026-04-09T06:37:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sbp-group-s-m701-bispecific-antibody-receives-nda-acceptance-for-malignant-ascites-treatment 2026-04-09T06:37:36+00:00 hourly 0.9 https://trial.medpath.com/news/triple-combination-pill-reduces-recurrent-stroke-risk-by-39-in-landmark-trident-trial 2026-04-09T05:04:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triple-combination-pill-reduces-recurrent-stroke-risk-by-39-in-landmark-trident-trial 2026-04-09T05:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/virica-biotech-and-fujifilm-biosciences-partner-to-enhance-aav-production-for-gene-therapy-manufacturing 2026-04-09T01:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virica-biotech-and-fujifilm-biosciences-partner-to-enhance-aav-production-for-gene-therapy-manufacturing 2026-04-09T01:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-medicine-launches-first-of-its-kind-compact-proton-therapy-system-treats-first-pediatric-patient 2026-04-09T01:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-medicine-launches-first-of-its-kind-compact-proton-therapy-system-treats-first-pediatric-patient 2026-04-09T01:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/proqr-partners-with-ginkgo-bioworks-to-accelerate-ai-driven-rna-editing-drug-discovery 2026-04-09T01:06:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proqr-partners-with-ginkgo-bioworks-to-accelerate-ai-driven-rna-editing-drug-discovery 2026-04-09T01:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/avita-medical-secures-25-5m-barda-contract-for-emergency-burn-treatment-preparedness 2026-04-09T01:06:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avita-medical-secures-25-5m-barda-contract-for-emergency-burn-treatment-preparedness 2026-04-09T01:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/neuroclues-secures-eur10-million-series-a-to-scale-ai-powered-eye-movement-biomarkers-for-neurological-diagnosis 2026-04-09T01:05:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuroclues-secures-eur10-million-series-a-to-scale-ai-powered-eye-movement-biomarkers-for-neurological-diagnosis 2026-04-09T01:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-digital-health-partners-with-enable-injections-to-develop-companion-digital-solution-for-enfuse-r-on-body-delivery-system 2026-04-09T01:05:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptar-digital-health-partners-with-enable-injections-to-develop-companion-digital-solution-for-enfuse-r-on-body-delivery-system 2026-04-09T01:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-s-anti-cd38-therapy-mezagitamab-achieves-91-response-rate-in-immune-thrombocytopenia-phase-ii-trial 2026-04-09T01:04:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-s-anti-cd38-therapy-mezagitamab-achieves-91-response-rate-in-immune-thrombocytopenia-phase-ii-trial 2026-04-09T01:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/nih-funded-team-based-care-model-achieves-significant-blood-pressure-reduction-in-underserved-populations 2026-04-09T01:04:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-funded-team-based-care-model-achieves-significant-blood-pressure-reduction-in-underserved-populations 2026-04-09T01:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-initiates-thetis-trial-testing-nereus-for-glp-1-receptor-agonist-induced-vomiting 2026-04-09T01:04:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanda-pharmaceuticals-initiates-thetis-trial-testing-nereus-for-glp-1-receptor-agonist-induced-vomiting 2026-04-09T01:04:53+00:00 hourly 0.9 https://trial.medpath.com/news/modular-medical-launches-patient-website-for-pivot-tubeless-insulin-patch-pump-following-fda-clearance 2026-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modular-medical-launches-patient-website-for-pivot-tubeless-insulin-patch-pump-following-fda-clearance 2026-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tavapadon-shows-promise-for-parkinson-s-disease-treatment-in-phase-3-trials 2026-04-08T21:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tavapadon-shows-promise-for-parkinson-s-disease-treatment-in-phase-3-trials 2026-04-08T21:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-licenses-ai-designed-aav-capsid-from-dyno-therapeutics-for-skeletal-muscle-gene-therapy 2026-04-08T21:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astellas-licenses-ai-designed-aav-capsid-from-dyno-therapeutics-for-skeletal-muscle-gene-therapy 2026-04-08T21:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/remedy-plan-therapeutics-strengthens-leadership-with-appointment-of-jotin-marango-as-cfo-and-cbo 2026-04-08T21:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remedy-plan-therapeutics-strengthens-leadership-with-appointment-of-jotin-marango-as-cfo-and-cbo 2026-04-08T21:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/fshd-society-launches-industry-collaborative-to-accelerate-clinical-trial-development-for-rare-muscular-dystrophy 2026-04-08T21:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fshd-society-launches-industry-collaborative-to-accelerate-clinical-trial-development-for-rare-muscular-dystrophy 2026-04-08T21:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/suven-s-ropanicant-meets-primary-endpoint-in-phase-2b-trial-for-major-depressive-disorder 2026-04-08T21:05:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/suven-s-ropanicant-meets-primary-endpoint-in-phase-2b-trial-for-major-depressive-disorder 2026-04-08T21:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/trogenix-s-gene-therapy-achieves-83-complete-tumor-elimination-in-glioblastoma-model-nature-study-shows 2026-04-08T21:04:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trogenix-s-gene-therapy-achieves-83-complete-tumor-elimination-in-glioblastoma-model-nature-study-shows 2026-04-08T21:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/tae-life-sciences-achieves-100-complete-response-rate-in-head-and-neck-cancer-with-novel-bnct-platform 2026-04-08T21:03:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tae-life-sciences-achieves-100-complete-response-rate-in-head-and-neck-cancer-with-novel-bnct-platform 2026-04-08T21:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/transformer-base-editor-shows-promise-in-first-clinical-trial-for-b-thalassaemia-treatment 2026-04-08T21:03:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transformer-base-editor-shows-promise-in-first-clinical-trial-for-b-thalassaemia-treatment 2026-04-08T21:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/spermosens-advances-juno-checked-generation-3-fertility-diagnostic-system-through-clinical-validation 2026-04-08T21:03:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spermosens-advances-juno-checked-generation-3-fertility-diagnostic-system-through-clinical-validation 2026-04-08T21:03:40+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-cdmo-facilities-achieve-major-manufacturing-milestones-as-biologics-production-capacity-expands 2026-04-08T17:10:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-cdmo-facilities-achieve-major-manufacturing-milestones-as-biologics-production-capacity-expands 2026-04-08T17:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/23andme-identifies-genetic-variants-that-predict-glp-1-drug-response-and-side-effects 2026-04-08T17:09:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/23andme-identifies-genetic-variants-that-predict-glp-1-drug-response-and-side-effects 2026-04-08T17:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/bioporto-divests-antibody-business-for-10-5m-to-focus-on-ngal-biomarker-development 2026-04-08T17:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioporto-divests-antibody-business-for-10-5m-to-focus-on-ngal-biomarker-development 2026-04-08T17:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/sidewinder-therapeutics-raises-137m-series-b-to-advance-next-generation-bispecific-adcs-for-cancer-treatment 2026-04-08T17:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sidewinder-therapeutics-raises-137m-series-b-to-advance-next-generation-bispecific-adcs-for-cancer-treatment 2026-04-08T17:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/organogenesis-puraply-am-shows-significant-efficacy-in-diabetic-foot-ulcer-trial 2026-04-08T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/organogenesis-puraply-am-shows-significant-efficacy-in-diabetic-foot-ulcer-trial 2026-04-08T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/stealth-biotherapeutics-appoints-david-a-brown-as-chief-scientific-officer-to-advance-mitochondrial-medicine-pipeline 2026-04-08T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stealth-biotherapeutics-appoints-david-a-brown-as-chief-scientific-officer-to-advance-mitochondrial-medicine-pipeline 2026-04-08T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/cortec-receives-fda-breakthrough-device-designation-for-brain-computer-interface-in-stroke-rehabilitation 2026-04-08T17:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cortec-receives-fda-breakthrough-device-designation-for-brain-computer-interface-in-stroke-rehabilitation 2026-04-08T17:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/swedish-government-invests-in-precision-medicine-cancer-studies-focu-se-and-sprintr-receive-major-funding 2026-04-08T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swedish-government-invests-in-precision-medicine-cancer-studies-focu-se-and-sprintr-receive-major-funding 2026-04-08T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/duloxetine-fails-to-prevent-oxaliplatin-induced-peripheral-neuropathy-in-colorectal-cancer-patients 2026-04-08T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duloxetine-fails-to-prevent-oxaliplatin-induced-peripheral-neuropathy-in-colorectal-cancer-patients 2026-04-08T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/modex-therapeutics-initiates-phase-1-trial-of-novel-tetravalent-covid-19-prevention-antibody-mdx2301 2026-04-08T17:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modex-therapeutics-initiates-phase-1-trial-of-novel-tetravalent-covid-19-prevention-antibody-mdx2301 2026-04-08T17:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-gene-silencing-drug-biib094-shows-promise-in-first-parkinson-s-disease-trial 2026-04-08T17:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-gene-silencing-drug-biib094-shows-promise-in-first-parkinson-s-disease-trial 2026-04-08T17:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-radiesse-for-decollete-wrinkle-treatment-marking-first-biostimulator-for-face-and-body-use 2026-04-08T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-radiesse-for-decollete-wrinkle-treatment-marking-first-biostimulator-for-face-and-body-use 2026-04-08T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-s-geography-problem-why-approval-doesn-t-equal-access 2026-04-08T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-s-geography-problem-why-approval-doesn-t-equal-access 2026-04-08T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/supira-medical-receives-fda-approval-for-support-ii-pivotal-trial-of-next-generation-percutaneous-ventricular-assist-device 2026-04-08T17:05:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supira-medical-receives-fda-approval-for-support-ii-pivotal-trial-of-next-generation-percutaneous-ventricular-assist-device 2026-04-08T17:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/waters-receives-fda-clearance-for-at-home-cervical-cancer-screening-kit 2026-04-08T17:04:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/waters-receives-fda-clearance-for-at-home-cervical-cancer-screening-kit 2026-04-08T17:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/purdue-pharma-s-novel-dual-mechanism-drug-tinostamustine-enters-phase-2-3-trial-for-glioblastoma 2026-04-08T17:04:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purdue-pharma-s-novel-dual-mechanism-drug-tinostamustine-enters-phase-2-3-trial-for-glioblastoma 2026-04-08T17:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/incyclix-bio-secures-5m-series-b-extension-to-advance-cdk2-inhibitor-inx-315-in-resistant-breast-and-ovarian-cancers 2026-04-08T13:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyclix-bio-secures-5m-series-b-extension-to-advance-cdk2-inhibitor-inx-315-in-resistant-breast-and-ovarian-cancers 2026-04-08T13:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/ani-pharmaceuticals-receives-fda-approval-for-generic-isosorbide-mononitrate-tablets 2026-04-08T13:06:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ani-pharmaceuticals-receives-fda-approval-for-generic-isosorbide-mononitrate-tablets 2026-04-08T13:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/hku-and-grand-pharmaceutical-form-strategic-partnership-to-develop-novel-anti-infective-therapies 2026-04-08T13:05:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hku-and-grand-pharmaceutical-form-strategic-partnership-to-develop-novel-anti-infective-therapies 2026-04-08T13:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/jeito-capital-closes-record-1-2-billion-fund-to-accelerate-european-biopharma-innovation 2026-04-08T09:07:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jeito-capital-closes-record-1-2-billion-fund-to-accelerate-european-biopharma-innovation 2026-04-08T09:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/metallium-secures-1m-pentagon-phase-ii-contract-for-critical-metal-recovery-technology 2026-04-08T09:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metallium-secures-1m-pentagon-phase-ii-contract-for-critical-metal-recovery-technology 2026-04-08T09:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/route-92-medical-secures-50-million-growth-financing-to-expand-revolutionary-stroke-treatment-technology 2026-04-08T09:05:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/route-92-medical-secures-50-million-growth-financing-to-expand-revolutionary-stroke-treatment-technology 2026-04-08T09:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/roosterbio-partners-with-minebio-to-expand-msc-and-exosome-manufacturing-solutions-in-china 2026-04-08T09:05:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roosterbio-partners-with-minebio-to-expand-msc-and-exosome-manufacturing-solutions-in-china 2026-04-08T09:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/huons-meditech-secures-nmpa-approval-for-premium-9pin-needle-in-china-s-aesthetic-market 2026-04-08T09:04:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huons-meditech-secures-nmpa-approval-for-premium-9pin-needle-in-china-s-aesthetic-market 2026-04-08T09:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-secures-482-million-barda-contract-to-strengthen-u-s-biodefense-against-drug-resistant-bacterial-threats 2026-04-08T09:04:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-secures-482-million-barda-contract-to-strengthen-u-s-biodefense-against-drug-resistant-bacterial-threats 2026-04-08T09:04:34+00:00 hourly 0.9 https://trial.medpath.com/news/methylscan-blood-test-achieves-93-8-accuracy-in-detecting-four-cancer-types-through-novel-dna-methylation-analysis 2026-04-08T05:07:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/methylscan-blood-test-achieves-93-8-accuracy-in-detecting-four-cancer-types-through-novel-dna-methylation-analysis 2026-04-08T05:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-mimics-exercise-benefits-in-prostate-cancer-patients-through-metabolic-pathway-activation 2026-04-08T05:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-mimics-exercise-benefits-in-prostate-cancer-patients-through-metabolic-pathway-activation 2026-04-08T05:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/neurotherapia-completes-phase-2a-trial-of-ntrx-07-for-alzheimer-s-disease-demonstrates-safety-and-target-engagement 2026-04-08T05:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurotherapia-completes-phase-2a-trial-of-ntrx-07-for-alzheimer-s-disease-demonstrates-safety-and-target-engagement 2026-04-08T05:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/biopharma-firms-shift-fda-approved-drug-manufacturing-to-europe-despite-us-tariffs-widening-outsourcing-gap-to-historic-levels 2026-04-08T03:04:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biopharma-firms-shift-fda-approved-drug-manufacturing-to-europe-despite-us-tariffs-widening-outsourcing-gap-to-historic-levels 2026-04-08T03:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/ai-designed-drug-gatc-1021-shows-promise-for-opioid-use-disorder-in-landmark-pnas-study 2026-04-08T01:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-designed-drug-gatc-1021-shows-promise-for-opioid-use-disorder-in-landmark-pnas-study 2026-04-08T01:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/novel-actinium-225-radioconjugate-shows-promise-against-treatment-resistant-her2-positive-breast-cancer 2026-04-08T01:05:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-actinium-225-radioconjugate-shows-promise-against-treatment-resistant-her2-positive-breast-cancer 2026-04-08T01:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-s-cefiderocol-shows-68-clinical-cure-rate-against-highly-resistant-mbl-producing-enterobacterales-in-real-world-study 2026-04-08T01:05:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-s-cefiderocol-shows-68-clinical-cure-rate-against-highly-resistant-mbl-producing-enterobacterales-in-real-world-study 2026-04-08T01:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/salk-institute-receives-41-3m-arpa-h-award-to-advance-sonogenetics-as-drug-free-therapy-for-peripheral-neuropathy 2026-04-08T01:04:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salk-institute-receives-41-3m-arpa-h-award-to-advance-sonogenetics-as-drug-free-therapy-for-peripheral-neuropathy 2026-04-08T01:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-discontinues-brensocatib-development-for-hidradenitis-suppurativa-after-phase-2b-trial-fails-to-meet-endpoints 2026-04-08T01:04:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insmed-discontinues-brensocatib-development-for-hidradenitis-suppurativa-after-phase-2b-trial-fails-to-meet-endpoints 2026-04-08T01:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/hexembio-secures-10-4m-to-advance-blood-stem-cell-rejuvenation-therapy-for-cancer-treatment 2026-04-07T21:10:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hexembio-secures-10-4m-to-advance-blood-stem-cell-rejuvenation-therapy-for-cancer-treatment 2026-04-07T21:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/samchundang-pharmaceutical-completes-global-patent-restructuring-for-s-pass-oral-drug-delivery-platform 2026-04-07T21:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samchundang-pharmaceutical-completes-global-patent-restructuring-for-s-pass-oral-drug-delivery-platform 2026-04-07T21:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/bioora-and-octane-biotech-partner-to-scale-car-t-manufacturing-using-automated-cocoon-platform 2026-04-07T21:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioora-and-octane-biotech-partner-to-scale-car-t-manufacturing-using-automated-cocoon-platform 2026-04-07T21:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/esmo-updates-metastatic-breast-cancer-guideline-molecular-subtyping-and-adcs-reshape-the-2026-treatment-landscape 2026-04-07T21:07:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esmo-updates-metastatic-breast-cancer-guideline-molecular-subtyping-and-adcs-reshape-the-2026-treatment-landscape 2026-04-07T21:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/insufficient-source-material-available-for-medical-news-article 2026-04-07T21:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insufficient-source-material-available-for-medical-news-article 2026-04-07T21:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/cornell-scientists-achieve-breakthrough-in-reversible-male-contraception-using-meiosis-disruption 2026-04-07T21:05:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cornell-scientists-achieve-breakthrough-in-reversible-male-contraception-using-meiosis-disruption 2026-04-07T21:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-nexus-aortic-arch-stent-graft-system-for-minimally-invasive-treatment-of-complex-aortic-disease 2026-04-07T21:05:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-nexus-aortic-arch-stent-graft-system-for-minimally-invasive-treatment-of-complex-aortic-disease 2026-04-07T21:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/merakris-therapeutics-reports-positive-interim-data-for-mtx-001-in-venous-leg-ulcers-advances-toward-late-stage-development 2026-04-07T17:09:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merakris-therapeutics-reports-positive-interim-data-for-mtx-001-in-venous-leg-ulcers-advances-toward-late-stage-development 2026-04-07T17:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/biorestorative-therapies-partners-with-leading-dermatologist-dr-david-goldberg-to-advance-regenerative-aesthetics-platform 2026-04-07T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biorestorative-therapies-partners-with-leading-dermatologist-dr-david-goldberg-to-advance-regenerative-aesthetics-platform 2026-04-07T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/inhibikase-therapeutics-initiates-phase-3-improve-pah-trial-for-novel-pulmonary-arterial-hypertension-treatment 2026-04-07T17:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhibikase-therapeutics-initiates-phase-3-improve-pah-trial-for-novel-pulmonary-arterial-hypertension-treatment 2026-04-07T17:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/tempramed-secures-key-patents-for-temperature-controlled-medication-storage-devices-in-brazil-and-india 2026-04-07T17:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempramed-secures-key-patents-for-temperature-controlled-medication-storage-devices-in-brazil-and-india 2026-04-07T17:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/catalym-initiates-phase-2b-trial-of-visugromab-in-second-line-hepatocellular-carcinoma-treatment 2026-04-07T17:06:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catalym-initiates-phase-2b-trial-of-visugromab-in-second-line-hepatocellular-carcinoma-treatment 2026-04-07T17:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/singlomics-initiates-first-in-human-trial-of-dxp-106-novel-il-1rap-antibody-for-advanced-solid-tumors 2026-04-07T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singlomics-initiates-first-in-human-trial-of-dxp-106-novel-il-1rap-antibody-for-advanced-solid-tumors 2026-04-07T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-denoza-apotex-s-denosumab-biosimilar-for-osteoporosis-treatment 2026-04-07T17:05:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-denoza-apotex-s-denosumab-biosimilar-for-osteoporosis-treatment 2026-04-07T17:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/alzheon-initiates-phase-1-trial-of-alz-507-next-generation-oral-alzheimer-s-drug-with-apoe4-corrector-mechanism 2026-04-07T17:05:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheon-initiates-phase-1-trial-of-alz-507-next-generation-oral-alzheimer-s-drug-with-apoe4-corrector-mechanism 2026-04-07T17:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/ac-immune-and-lilly-expand-tau-targeting-collaboration-with-chf-10-million-amendment-for-alzheimer-s-disease 2026-04-07T13:05:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ac-immune-and-lilly-expand-tau-targeting-collaboration-with-chf-10-million-amendment-for-alzheimer-s-disease 2026-04-07T13:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/south-korea-approves-two-orphan-drugs-for-hiv-and-lung-cancer-patients-with-limited-treatment-options 2026-04-07T13:05:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-korea-approves-two-orphan-drugs-for-hiv-and-lung-cancer-patients-with-limited-treatment-options 2026-04-07T13:05:09+00:00 hourly 0.9 https://trial.medpath.com/news/allelica-partners-with-mass-general-brigham-for-proact-3-trial-testing-polygenic-risk-score-impact-on-cardiovascular-prevention 2026-04-07T13:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allelica-partners-with-mass-general-brigham-for-proact-3-trial-testing-polygenic-risk-score-impact-on-cardiovascular-prevention 2026-04-07T13:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/abion-s-abn202-demonstrates-superior-anti-cancer-activity-over-trop2-targeting-adcs-in-preclinical-studies 2026-04-07T09:06:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abion-s-abn202-demonstrates-superior-anti-cancer-activity-over-trop2-targeting-adcs-in-preclinical-studies 2026-04-07T09:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/renovare-therapeutics-emerges-from-stealth-mode-with-33-5m-arpa-h-funding-for-osteoarthritis-regenerative-therapies 2026-04-07T09:05:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renovare-therapeutics-emerges-from-stealth-mode-with-33-5m-arpa-h-funding-for-osteoarthritis-regenerative-therapies 2026-04-07T09:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-dual-target-bispecific-lunsekimig-shows-promise-in-phase-2-respiratory-disease-studies 2026-04-07T09:04:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-dual-target-bispecific-lunsekimig-shows-promise-in-phase-2-respiratory-disease-studies 2026-04-07T09:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/valitor-s-vltr-559-shows-extended-six-month-durability-in-wet-amd-preclinical-studies 2026-04-07T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valitor-s-vltr-559-shows-extended-six-month-durability-in-wet-amd-preclinical-studies 2026-04-07T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/radiopharmaceutical-development-faces-translational-bottleneck-as-field-accelerates 2026-04-07T06:45:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiopharmaceutical-development-faces-translational-bottleneck-as-field-accelerates 2026-04-07T06:45:51+00:00 hourly 0.9 https://trial.medpath.com/news/invera-medical-receives-fda-clearance-for-novel-non-thermal-catheter-device-for-chronic-venous-disease-treatment 2026-04-07T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invera-medical-receives-fda-clearance-for-novel-non-thermal-catheter-device-for-chronic-venous-disease-treatment 2026-04-07T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vanderbilt-center-partners-with-saravir-biopharma-to-develop-novel-monoclonal-antibody-therapy-for-measles 2026-04-07T01:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanderbilt-center-partners-with-saravir-biopharma-to-develop-novel-monoclonal-antibody-therapy-for-measles 2026-04-07T01:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/colorado-legislature-considers-exempting-orphan-drugs-from-state-pricing-caps-amid-industry-and-consumer-advocacy-debate 2026-04-07T01:05:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/colorado-legislature-considers-exempting-orphan-drugs-from-state-pricing-caps-amid-industry-and-consumer-advocacy-debate 2026-04-07T01:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/artemilife-s-artemisia-infused-coffee-nears-phase-2-completion-for-prostate-cancer-maintenance-therapy 2026-04-07T01:05:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artemilife-s-artemisia-infused-coffee-nears-phase-2-completion-for-prostate-cancer-maintenance-therapy 2026-04-07T01:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/pol-theta-enzyme-drives-dna-repair-at-broken-replication-forks-revealing-new-cancer-vulnerability 2026-04-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pol-theta-enzyme-drives-dna-repair-at-broken-replication-forks-revealing-new-cancer-vulnerability 2026-04-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/merit-medical-acquires-view-point-medical-for-140-million-to-expand-breast-cancer-localization-portfolio 2026-04-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merit-medical-acquires-view-point-medical-for-140-million-to-expand-breast-cancer-localization-portfolio 2026-04-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/apple-s-studio-display-xdr-receives-fda-clearance-for-medical-imaging-applications 2026-04-06T21:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apple-s-studio-display-xdr-receives-fda-clearance-for-medical-imaging-applications 2026-04-06T21:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/evommune-s-evo756-misses-primary-endpoint-in-phase-2b-chronic-spontaneous-urticaria-trial-pivots-to-atopic-dermatitis-and-migraine 2026-04-06T21:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evommune-s-evo756-misses-primary-endpoint-in-phase-2b-chronic-spontaneous-urticaria-trial-pivots-to-atopic-dermatitis-and-migraine 2026-04-06T21:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/alar-pharmaceuticals-reports-breakthrough-phase-1-results-for-long-acting-ketamine-injectable-ala-3000-in-treatment-resistant-depression 2026-04-06T21:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alar-pharmaceuticals-reports-breakthrough-phase-1-results-for-long-acting-ketamine-injectable-ala-3000-in-treatment-resistant-depression 2026-04-06T21:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/upsher-smith-expands-generic-portfolio-with-launch-of-cyclosporine-ophthalmic-emulsion-targeting-1-9-billion-market 2026-04-06T21:05:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upsher-smith-expands-generic-portfolio-with-launch-of-cyclosporine-ophthalmic-emulsion-targeting-1-9-billion-market 2026-04-06T21:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/delfi-diagnostics-presents-five-studies-on-ai-driven-cfdna-platform-for-cancer-detection-and-monitoring-at-aacr-2026 2026-04-06T17:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delfi-diagnostics-presents-five-studies-on-ai-driven-cfdna-platform-for-cancer-detection-and-monitoring-at-aacr-2026 2026-04-06T17:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/tenvie-therapeutics-initiates-first-in-human-trial-of-cns-penetrant-nlrp3-inhibitor-tnv262-for-obesity-and-cardiovascular-disease 2026-04-06T17:07:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenvie-therapeutics-initiates-first-in-human-trial-of-cns-penetrant-nlrp3-inhibitor-tnv262-for-obesity-and-cardiovascular-disease 2026-04-06T17:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-subcutaneous-tepezza-shows-77-response-rate-in-phase-3-thyroid-eye-disease-trial 2026-04-06T17:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-subcutaneous-tepezza-shows-77-response-rate-in-phase-3-thyroid-eye-disease-trial 2026-04-06T17:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/iavi-initiates-first-in-human-trial-of-single-dose-marburg-virus-vaccine-candidate 2026-04-06T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iavi-initiates-first-in-human-trial-of-single-dose-marburg-virus-vaccine-candidate 2026-04-06T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/sk-life-science-to-present-comprehensive-cenobamate-data-and-patient-provider-communication-study-at-aan-2026 2026-04-06T17:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-life-science-to-present-comprehensive-cenobamate-data-and-patient-provider-communication-study-at-aan-2026 2026-04-06T17:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/isatuximab-based-quadruplet-therapy-significantly-improves-mrd-negativity-in-newly-diagnosed-multiple-myeloma 2026-04-06T17:05:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isatuximab-based-quadruplet-therapy-significantly-improves-mrd-negativity-in-newly-diagnosed-multiple-myeloma 2026-04-06T17:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/united-health-products-secures-fda-approval-for-new-clinical-study-partnership-to-advance-cellustat-hemostatic-gauze 2026-04-06T17:05:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-health-products-secures-fda-approval-for-new-clinical-study-partnership-to-advance-cellustat-hemostatic-gauze 2026-04-06T17:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-edinburgh-researchers-identify-key-cellular-mechanism-driving-fibrosis-in-crohn-s-disease 2026-04-06T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-edinburgh-researchers-identify-key-cellular-mechanism-driving-fibrosis-in-crohn-s-disease 2026-04-06T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/the-rise-of-unregulated-wellness-peptides-experts-warn-of-safety-gaps-and-unknown-long-term-risks 2026-04-06T17:05:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-rise-of-unregulated-wellness-peptides-experts-warn-of-safety-gaps-and-unknown-long-term-risks 2026-04-06T17:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/beacon-biosignals-raises-97-million-series-b-to-advance-at-home-eeg-brain-health-platform 2026-04-06T13:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beacon-biosignals-raises-97-million-series-b-to-advance-at-home-eeg-brain-health-platform 2026-04-06T13:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/stipple-bio-secures-100-million-series-a-to-advance-novel-adc-platform-targeting-tumor-specific-epitopes 2026-04-06T13:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stipple-bio-secures-100-million-series-a-to-advance-novel-adc-platform-targeting-tumor-specific-epitopes 2026-04-06T13:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/biocryst-pharmaceuticals-appoints-sandeep-m-menon-as-chief-research-and-development-officer 2026-04-06T13:06:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocryst-pharmaceuticals-appoints-sandeep-m-menon-as-chief-research-and-development-officer 2026-04-06T13:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/kowa-s-k-679-aduc-achieves-ultra-high-drug-loading-with-superior-tumor-distribution-in-preclinical-studies 2026-04-06T13:06:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kowa-s-k-679-aduc-achieves-ultra-high-drug-loading-with-superior-tumor-distribution-in-preclinical-studies 2026-04-06T13:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/quizartinib-combination-therapy-shows-promise-in-phase-ii-trial-for-flt3-itd-aml 2026-04-06T13:05:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quizartinib-combination-therapy-shows-promise-in-phase-ii-trial-for-flt3-itd-aml 2026-04-06T13:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-acquires-soleno-therapeutics-for-2-9-billion-adding-first-in-class-pws-treatment 2026-04-06T13:05:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-biosciences-acquires-soleno-therapeutics-for-2-9-billion-adding-first-in-class-pws-treatment 2026-04-06T13:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/profusa-expands-into-precision-diagnostics-with-30m-panomics-platform-acquisition-and-mayo-clinic-partnership 2026-04-06T13:05:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/profusa-expands-into-precision-diagnostics-with-30m-panomics-platform-acquisition-and-mayo-clinic-partnership 2026-04-06T13:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/humira-biosimilar-uptake-surges-after-cvs-formulary-change-then-declines-amid-nocebo-effect-concerns 2026-04-05T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/humira-biosimilar-uptake-surges-after-cvs-formulary-change-then-declines-amid-nocebo-effect-concerns 2026-04-05T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/catheter-precision-presents-new-clinical-data-for-vivo-and-locket-systems-at-heart-rhythm-society-meeting 2026-04-05T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catheter-precision-presents-new-clinical-data-for-vivo-and-locket-systems-at-heart-rhythm-society-meeting 2026-04-05T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/corflow-therapeutics-advances-heart-attack-treatment-with-successful-phase-1-completion-and-phase-2-initiation-of-moca-ii-pivotal-trial 2026-04-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corflow-therapeutics-advances-heart-attack-treatment-with-successful-phase-1-completion-and-phase-2-initiation-of-moca-ii-pivotal-trial 2026-04-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/indian-cancer-drug-manufacturers-seek-50-price-increase-as-platinum-costs-surge 2026-04-05T21:18:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-cancer-drug-manufacturers-seek-50-price-increase-as-platinum-costs-surge 2026-04-05T21:18:19+00:00 hourly 0.9 https://trial.medpath.com/news/abu-dhabi-advances-neural-stem-cell-research-with-patient-derived-cell-reprogramming-technology 2026-04-05T13:04:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abu-dhabi-advances-neural-stem-cell-research-with-patient-derived-cell-reprogramming-technology 2026-04-05T13:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-restores-hearing-in-90-of-patients-with-genetic-deafness-in-landmark-clinical-trial 2026-04-05T05:04:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-restores-hearing-in-90-of-patients-with-genetic-deafness-in-landmark-clinical-trial 2026-04-05T05:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-real-world-study-reveals-safer-second-line-diabetes-drug-options-for-elderly-patients 2026-04-05T01:04:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-real-world-study-reveals-safer-second-line-diabetes-drug-options-for-elderly-patients 2026-04-05T01:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/telomir-pharmaceuticals-secures-global-rights-to-telomir-1-through-teli-acquisition-advances-toward-triple-negative-breast-cancer-trial 2026-04-04T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telomir-pharmaceuticals-secures-global-rights-to-telomir-1-through-teli-acquisition-advances-toward-triple-negative-breast-cancer-trial 2026-04-04T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-faces-pressure-to-reverse-peptide-safety-restrictions-under-kennedy-leadership 2026-04-04T01:04:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-faces-pressure-to-reverse-peptide-safety-restrictions-under-kennedy-leadership 2026-04-04T01:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-announces-major-restructuring-with-247-job-cuts-in-massachusetts-to-fund-late-stage-pipeline 2026-04-03T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-announces-major-restructuring-with-247-job-cuts-in-massachusetts-to-fund-late-stage-pipeline 2026-04-03T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/cocoon-trial-prophylactic-dermatologic-protocol-halves-skin-toxicities-in-egfr-mutant-nsclc-patients-on-amivantamab-lazertinib 2026-04-03T21:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cocoon-trial-prophylactic-dermatologic-protocol-halves-skin-toxicities-in-egfr-mutant-nsclc-patients-on-amivantamab-lazertinib 2026-04-03T21:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/gi-innovation-advances-cancer-immunotherapy-pipeline-with-asco-presentation-and-phase-2-trial-approval 2026-04-03T21:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gi-innovation-advances-cancer-immunotherapy-pipeline-with-asco-presentation-and-phase-2-trial-approval 2026-04-03T21:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-sciences-terminates-hiv-drug-trial-after-fda-maintains-safety-hold 2026-04-03T21:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-sciences-terminates-hiv-drug-trial-after-fda-maintains-safety-hold 2026-04-03T21:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-recalls-over-3-million-eye-drop-bottles-due-to-sterility-concerns 2026-04-03T21:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-recalls-over-3-million-eye-drop-bottles-due-to-sterility-concerns 2026-04-03T21:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/targeted-electroacupuncture-shows-promise-for-cognitive-symptoms-in-breast-cancer-survivors 2026-04-03T21:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeted-electroacupuncture-shows-promise-for-cognitive-symptoms-in-breast-cancer-survivors 2026-04-03T21:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/rhythm-pharmaceuticals-appoints-kim-popovits-to-board-of-directors-as-ed-mathers-departs 2026-04-03T17:07:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rhythm-pharmaceuticals-appoints-kim-popovits-to-board-of-directors-as-ed-mathers-departs 2026-04-03T17:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-rules-omitted-coinventor-renders-patents-invalid-when-correction-procedures-cannot-be-met 2026-04-03T17:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-rules-omitted-coinventor-renders-patents-invalid-when-correction-procedures-cannot-be-met 2026-04-03T17:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/texas-biomed-researchers-test-first-potential-measles-treatment-as-cases-surge-nationwide 2026-04-03T17:05:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-biomed-researchers-test-first-potential-measles-treatment-as-cases-surge-nationwide 2026-04-03T17:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-drug-cn-105-shows-promise-in-reducing-postoperative-delirium-in-older-adults 2026-04-03T17:04:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-drug-cn-105-shows-promise-in-reducing-postoperative-delirium-in-older-adults 2026-04-03T17:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-finds-enzyme-blend-eases-joint-pain-in-92-of-dogs-with-arthritis 2026-04-03T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-finds-enzyme-blend-eases-joint-pain-in-92-of-dogs-with-arthritis 2026-04-03T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/anthropic-acquires-ai-biotech-startup-coefficient-bio-for-400-million-to-advance-drug-discovery 2026-04-03T09:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anthropic-acquires-ai-biotech-startup-coefficient-bio-for-400-million-to-advance-drug-discovery 2026-04-03T09:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/oral-drug-n-ppg-shows-complete-prevention-of-kidney-stones-and-death-in-rare-disease-model 2026-04-03T05:13:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-drug-n-ppg-shows-complete-prevention-of-kidney-stones-and-death-in-rare-disease-model 2026-04-03T05:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/cipla-receives-fda-approval-for-generic-nintedanib-capsules-to-treat-idiopathic-pulmonary-fibrosis 2026-04-03T05:12:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cipla-receives-fda-approval-for-generic-nintedanib-capsules-to-treat-idiopathic-pulmonary-fibrosis 2026-04-03T05:12:49+00:00 hourly 0.9 https://trial.medpath.com/news/high-dose-flu-vaccine-linked-to-55-lower-alzheimer-s-risk-in-adults-over-65 2026-04-03T05:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-dose-flu-vaccine-linked-to-55-lower-alzheimer-s-risk-in-adults-over-65 2026-04-03T05:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/iterative-health-expands-cardiovascular-research-network-through-strategic-partnership-and-acquisition 2026-04-03T05:10:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iterative-health-expands-cardiovascular-research-network-through-strategic-partnership-and-acquisition 2026-04-03T05:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-partners-with-trinetx-in-200-million-deal-to-access-300-million-patient-health-records-for-drug-discovery 2026-04-03T01:15:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-partners-with-trinetx-in-200-million-deal-to-access-300-million-patient-health-records-for-drug-discovery 2026-04-03T01:15:32+00:00 hourly 0.9 https://trial.medpath.com/news/ultrasensitive-blood-test-hpv-deepseek-predicts-recurrence-and-survival-in-hpv-associated-head-and-neck-cancer 2026-04-02T21:21:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultrasensitive-blood-test-hpv-deepseek-predicts-recurrence-and-survival-in-hpv-associated-head-and-neck-cancer 2026-04-02T21:21:43+00:00 hourly 0.9 https://trial.medpath.com/news/perceptive-discovery-expands-in-vitro-capabilities-with-five-fold-facility-increase-to-accelerate-oncology-drug-development 2026-04-02T21:14:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perceptive-discovery-expands-in-vitro-capabilities-with-five-fold-facility-increase-to-accelerate-oncology-drug-development 2026-04-02T21:14:46+00:00 hourly 0.9 https://trial.medpath.com/news/st-jude-scientists-discover-how-to-restore-dendritic-cell-function-to-enhance-cancer-immunotherapy 2026-04-02T21:12:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/st-jude-scientists-discover-how-to-restore-dendritic-cell-function-to-enhance-cancer-immunotherapy 2026-04-02T21:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/acurion-raises-4-3-million-to-advance-ai-powered-cancer-biomarker-detection-platform 2026-04-02T21:10:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acurion-raises-4-3-million-to-advance-ai-powered-cancer-biomarker-detection-platform 2026-04-02T21:10:39+00:00 hourly 0.9 https://trial.medpath.com/news/o-shaughnessy-ventures-backs-bioengineer-developing-gene-therapy-for-rare-muscular-dystrophy-she-lives-with 2026-04-02T21:10:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/o-shaughnessy-ventures-backs-bioengineer-developing-gene-therapy-for-rare-muscular-dystrophy-she-lives-with 2026-04-02T21:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-three-existing-drugs-with-potential-for-epilepsy-treatment-through-computational-screening 2026-04-02T20:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-identify-three-existing-drugs-with-potential-for-epilepsy-treatment-through-computational-screening 2026-04-02T20:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-dual-hif-1-2-inhibitors-achieve-complete-tumor-remission-in-combination-with-immunotherapy 2026-04-02T17:10:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-dual-hif-1-2-inhibitors-achieve-complete-tumor-remission-in-combination-with-immunotherapy 2026-04-02T17:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/mission-biocapital-opens-4-million-2026-platinum-program-for-global-biotech-startups 2026-04-02T17:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mission-biocapital-opens-4-million-2026-platinum-program-for-global-biotech-startups 2026-04-02T17:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/panoramic-health-and-west-coast-kidney-institute-launch-specialized-research-institute-for-cardio-renal-metabolic-trials 2026-04-02T17:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panoramic-health-and-west-coast-kidney-institute-launch-specialized-research-institute-for-cardio-renal-metabolic-trials 2026-04-02T17:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/neutrolis-reports-positive-phase-1a-results-for-first-in-class-net-targeting-therapy-ntr-1011 2026-04-02T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neutrolis-reports-positive-phase-1a-results-for-first-in-class-net-targeting-therapy-ntr-1011 2026-04-02T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/glycomine-completes-enrollment-in-phase-2b-polar-study-of-glm101-for-rare-genetic-disorder-pmm2-cdg 2026-04-02T17:07:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glycomine-completes-enrollment-in-phase-2b-polar-study-of-glm101-for-rare-genetic-disorder-pmm2-cdg 2026-04-02T17:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/earendil-labs-initiates-phase-iia-trial-of-half-life-extended-anti-tl1a-antibody-hxn-1001-for-ulcerative-colitis 2026-04-02T17:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/earendil-labs-initiates-phase-iia-trial-of-half-life-extended-anti-tl1a-antibody-hxn-1001-for-ulcerative-colitis 2026-04-02T17:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/palleon-pharmaceuticals-to-present-first-in-class-b7-h3-targeted-sialidase-hlx316-e-688-at-aacr-2026 2026-04-02T17:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palleon-pharmaceuticals-to-present-first-in-class-b7-h3-targeted-sialidase-hlx316-e-688-at-aacr-2026 2026-04-02T17:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/cellcarta-and-pillar-biosciences-form-strategic-partnership-to-accelerate-ngs-tumor-profiling-for-oncology-trials 2026-04-02T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellcarta-and-pillar-biosciences-form-strategic-partnership-to-accelerate-ngs-tumor-profiling-for-oncology-trials 2026-04-02T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/oncotelic-therapeutics-partners-with-techforce-robotics-to-commercialize-ai-enhanced-gmp-manufacturing-platform 2026-04-02T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncotelic-therapeutics-partners-with-techforce-robotics-to-commercialize-ai-enhanced-gmp-manufacturing-platform 2026-04-02T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/canwell-pharma-receives-fda-clearance-for-can016-dual-payload-adc-in-her2-positive-tumors 2026-04-02T17:06:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canwell-pharma-receives-fda-clearance-for-can016-dual-payload-adc-in-her2-positive-tumors 2026-04-02T17:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-completes-acquisition-of-jsr-chromatography-business-to-expand-protein-a-purification-capabilities 2026-04-02T17:06:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-kgaa-completes-acquisition-of-jsr-chromatography-business-to-expand-protein-a-purification-capabilities 2026-04-02T17:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/triple-hair-initiates-phase-iii-trial-for-th07-triple-combination-therapy-in-male-pattern-baldness 2026-04-02T17:05:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triple-hair-initiates-phase-iii-trial-for-th07-triple-combination-therapy-in-male-pattern-baldness 2026-04-02T17:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/context-therapeutics-receives-fda-fast-track-designation-for-ctim-76-in-platinum-resistant-ovarian-cancer 2026-04-02T13:05:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/context-therapeutics-receives-fda-fast-track-designation-for-ctim-76-in-platinum-resistant-ovarian-cancer 2026-04-02T13:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/immunovant-s-batoclimab-fails-phase-3-thyroid-eye-disease-trials-despite-early-promise 2026-04-02T13:04:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunovant-s-batoclimab-fails-phase-3-thyroid-eye-disease-trials-despite-early-promise 2026-04-02T13:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/priovant-launches-phase-2b-3-trial-for-brepocitinib-in-lichen-planopilaris-targeting-rare-scarring-hair-loss-disorder 2026-04-02T13:04:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/priovant-launches-phase-2b-3-trial-for-brepocitinib-in-lichen-planopilaris-targeting-rare-scarring-hair-loss-disorder 2026-04-02T13:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-biontech-halt-covid-19-vaccine-trial-for-adults-50-64-due-to-enrollment-challenges 2026-04-02T13:04:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-biontech-halt-covid-19-vaccine-trial-for-adults-50-64-due-to-enrollment-challenges 2026-04-02T13:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/merck-initiates-pivotal-phase-2b-3-trial-for-novel-bispecific-antibody-mk-8748-in-wet-age-related-macular-degeneration 2026-04-02T13:04:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-initiates-pivotal-phase-2b-3-trial-for-novel-bispecific-antibody-mk-8748-in-wet-age-related-macular-degeneration 2026-04-02T13:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/avencell-doses-first-patient-with-world-s-first-crispr-engineered-dual-targeting-allogeneic-car-t-therapy 2026-04-02T13:03:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avencell-doses-first-patient-with-world-s-first-crispr-engineered-dual-targeting-allogeneic-car-t-therapy 2026-04-02T13:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/middle-east-disruption-impacts-6-7-of-global-clinical-trials-threatening-drug-development-pipeline 2026-04-02T13:03:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/middle-east-disruption-impacts-6-7-of-global-clinical-trials-threatening-drug-development-pipeline 2026-04-02T13:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/aneuvo-secures-fda-clearance-for-exastim-spinal-cord-stimulation-system-following-22m-series-c 2026-04-02T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aneuvo-secures-fda-clearance-for-exastim-spinal-cord-stimulation-system-following-22m-series-c 2026-04-02T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/medibeacon-s-transdermal-kidney-function-monitor-receives-european-ce-mark-certification 2026-04-02T09:04:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medibeacon-s-transdermal-kidney-function-monitor-receives-european-ce-mark-certification 2026-04-02T09:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/generare-secures-eur20m-series-a-to-unlock-cryptic-molecular-chemistry-from-microbial-genomes 2026-04-02T09:03:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/generare-secures-eur20m-series-a-to-unlock-cryptic-molecular-chemistry-from-microbial-genomes 2026-04-02T09:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-second-glp-1-pill-for-weight-loss-with-fewer-usage-restrictions 2026-04-02T05:03:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-second-glp-1-pill-for-weight-loss-with-fewer-usage-restrictions 2026-04-02T05:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/digital-twin-hearts-show-100-success-rate-in-first-clinical-trial-for-ventricular-tachycardia-ablation 2026-04-02T01:13:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digital-twin-hearts-show-100-success-rate-in-first-clinical-trial-for-ventricular-tachycardia-ablation 2026-04-02T01:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/uspto-introduces-new-pre-order-procedure-to-address-patent-reexamination-gaming-tactics 2026-04-02T01:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uspto-introduces-new-pre-order-procedure-to-address-patent-reexamination-gaming-tactics 2026-04-02T01:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/onemednet-partners-with-onco-innovations-to-accelerate-pnkp-inhibitor-development-using-ai-powered-real-world-data 2026-04-02T01:09:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onemednet-partners-with-onco-innovations-to-accelerate-pnkp-inhibitor-development-using-ai-powered-real-world-data 2026-04-02T01:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/dulaglutide-shows-promise-for-coronary-plaque-stabilization-in-type-2-diabetes-patients 2026-04-02T01:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dulaglutide-shows-promise-for-coronary-plaque-stabilization-in-type-2-diabetes-patients 2026-04-02T01:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-ceo-opposes-congressional-codification-of-trump-s-most-favored-nation-drug-pricing-deals 2026-04-02T01:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-ceo-opposes-congressional-codification-of-trump-s-most-favored-nation-drug-pricing-deals 2026-04-02T01:08:26+00:00 hourly 0.9